Novel compounds as modulators of il17

Abstract

The present invention relates to novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, their polymorphs, their racemic mixtures, their optically active forms and their use in the treatment of inflammatory conditions such as psoriasis, asthma, psoriatic arthritis or rheumatoid arthritis. Further, the present invention relates to processes of preparing such compounds, novel intermediates involved in their synthesis.

Description

[0001] NOVEL COMPOUNDS AS MODULATORS OF IL17 FIELD OF INVENTION The present invention relates to novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, their polymorphs, their racemic mixtures, their optically active forms and their use in the treatment of inflammatory conditions such as psoriasis, asthma, psoriatic arthritis or rheumatoid arthritis. Further, the present invention relates to processes of preparing such compounds, novel intermediates involved in their synthesis. BACKGROUND OF THE INVENTION Interleukin-17 (IL-17) is a pro-inflammatory cytokine that contributes to the pathogenesis of several inflammatory diseases. The IL-17 family of cytokines consists of six isoforms (IL-17A- IL-17F) and five receptors, IL-17RA-E. IL-17A is the prototype and the best-studied member of IL-17 family, and it shares the highest sequence homology with IL-17F at 50%. IL-17A and IL- 17F are known to form tightly associated homodimers, but IL-17A / F heterodimers have also been identified in vivo. IL-17RA is the prototype of IL-17R family and a shared receptor for at least IL-17A, IL-17C, IL-17E, IL-17F, and IL-17A / F signaling. IL-17RA pairs with other IL- 17R members to form heterodimeric receptor complexes on the cell surface for differential IL-17 cytokine signaling. IL-17A and IL-17F signaling through the cell surface receptor complex consists of IL-17RA and IL-17RC. Both IL-17RA and IL-17RC consist of a large extracellular domain, a single-pass transmembrane helix, and an intracellular signaling motif referred to as the SEFIR domain that drives downstream signaling. Antagonizing IL-17A / IL-17RA protein–protein interaction (PPI) was hypothesized to reduce over exaggerated inflammation in autoimmune diseases. There are several ways to block IL-17A signaling by targeting IL-17A proteins or receptors. Clinically, three monoclonal antibodies (mAbs) are already approved for different immunological diseases, secukinumab and ixekizumab target IL-17A while brodalumab targets IL-17RA. Numerous clinical trials of anti- IL-17A and IL-17RA antibodies are currently in progress. IL-17A / IL-17RA directed biotherapeutics have achieved impressive successes in durable clinical treatment of psoriasis, asthma, psoriatic arthritis, and rheumatoid arthritis. However, IL17A has also major implications in central nervous system neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and glaucoma. There have been three IL-17 inhibitors approved by USFDA which are monoclonal antibodies (mAbs). There is no drug approved which belongs to the small-molecule class. Some of the patents which disclose small-molecule IL-17 inhibitors are WO 2019138017, WO 2020127685, WO 2020120141, WO 2020182666, WO 2021239745, WO 2021055376, WO 2021250194, WO 2021239743, WO 2022091056, WO 2022007462 and WO 2023225664. However, mAbs have limited applications due to non-oral administration, poor tissue penetration, lacking blood-brain barrier penetration, often long half-life times, high cost-of-good, and most importantly being applicable only to extracellular targets. For these reasons, the development of small-molecule modulators targeting IL- 17A / IL-17RA is an emerging area, which potentially could considerably widen current indication areas. Small molecules generally have a good tissue penetration with potentially higher efficacy and a tunable half-life time and are orally bioavailable facilitating patient treatment. SUMMARY OF THE INVENTION The invention provides compounds which are active to control IL17A mediated pathways and their use for the treatment of inflammatory diseases. The novel compounds are defined by the general formula (1) as given below. The compounds of the present invention are useful for human treatment or for veterinary treatment of animal. The compounds of this invention are therefore suitable for the treatment / mitigation / regulation or prophylaxis of inflammatory diseases. EMBODIMENTS OF THE INVENTION The main objective of the present invention is to provide novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, novel intermediates involved in their synthesis, their polymorphs, their racemic mixtures and their optically active forms or their mixtures suitable for the treatment of inflammatory diseases. In an embodiment is provided a process for the preparation of novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, novel intermediates involved in their synthesis, their polymorphs, their racemic mixtures and their optically active forms. In another embodiment is provided pharmaceutical compositions comprising the novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, novel intermediates involved in their synthesis, their polymorphs, their racemic mixtures and their optically active forms having pharmaceutically acceptable carriers, solvents, diluents, binder, disintegrant, coating agent, filler, glidant, and / or other suitable excipients. In a further another embodiment is provided the use of the novel compounds of the present invention for the treatment of inflammatory diseases, by administering a therapeutically effective & non-toxic amount of novel compounds of general formula (1) or their pharmaceutically acceptable salts, or their pharmaceutically acceptable compositions. In yet another embodiment is provided a method of treating inflammatory diseases using novel compounds of general formula (1) or their pharmaceutically acceptable salts, or their pharmaceutically acceptable compositions. DETAILED DESCRIPTION: In a preferred embodiment, the groups referred to above may comprise of: - the “alkyl” group used either alone or in combination with other radicals, denotes a linear or branched radical containing one to six carbons, selected from -CH, -CH2, methyl, ethyl, n- propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, amyl, t-amyl, n-pentyl, n-hexyl, and the like; - the “cycloalkyl”, or “alicyclic” group used either alone or in combination with other radicals, is selected from a cyclic radical containing three to six carbons, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like; - the “heterocyclylalkyl” group used either alone or in combination with other radicals, is selected from groups containing an heterocyclyl radical, as defined above, attached directly to an alkyl radical, as define above; - the “haloalkyl” group is selected from an alkyl radical, as defined above, suitably substituted with one or more halogens; such as fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, mono or polyhalo substituted methyl, ethyl, propyl, butyl, pentyl or hexyl groups; - "halo" or "halogen" by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom; - the “aryl” or “aromatic” group used either alone or in combination with other radicals, is selected from a suitable aromatic system containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused, more preferably the groups are selected from phenyl, naphthyl, tetrahydronaphthyl, indane, biphenyl, and the like; - the “heteroaryl” or “heteroaromatic” group used either alone or in combination with other radicals, is selected from suitable single or fused mono, bi or tricyclic aromatic heterocyclic radicals containing one or more hetero atoms selected from O, N or S, more preferably the groups are selected from pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, benzofuranyl, benzothienyl, indolinyl, indolyl, azaindolyl, azaindolinyl, pyrazolopyrimidinyl, azaquinazolinyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl, pyridazinyl, triazinyl, benzimidazolyl, benzotriazolyl, phthalazynil, naphthylidinyl, purinyl, carbazolyl, phenothiazinyl, phenoxazinyl, benzoxazolyl, benzothiazolyl and the like; - the “carbocycle” group used either alone or in combination with other radicals, is selected from groups as described in “cycloalkyl” or “aryl” or “aromatic”; - the term “cycloalkene” used anywhere in the specification indicates hydrocarbons containing a ring of carbon atoms and one or more double bonds in the cycle that do not form an aromatic ring, for example but not limited to cyclohexene, cyclopentene, cyclohexa-1,4- diene, cycloheptene; - the term “cycloalkyne” used anywhere in the specification indicates hydrocarbons containing a ring of carbon atoms and one or more triple bonds in the cycle that do not form an aromatic ring, for example but not limited to cyclohexyne, cyclopentyne, cyclohexa-1,4-diyne, cycloheptyne; - The “spirocyclic ring system” when there are two positions for substitution on the same atom, for example but not limited to spiro[2.5]octanyl, spiro[4.5]decanyl, or spiro[5.5]undecanyl, 2-oxa- 7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl and 6-oxa- l-azaspiro[3.3]heptanyl; - As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 4 to 14-membered heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms & also contains from 1 to 3 hetero atoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The term heterocycle as used in the specification includes both aromatic and non-aromatic single or fused cyclic system containing at least one heteroatom selected from N, O and S. The nitrogen and sulfur hetero atoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. A skilled person is well aware of the terms "heterocycle" or "heterocyclic system" and the present invention encompasses all such variations, alterations of definitions which are within the scope of such a skilled person. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. In a further optional embodiment, nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these hetero atoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. As used herein, the term "aromatic heterocyclic system" is intended to mean a stable bicyclic or 8 to 14 membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S. It is preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 1. Also included are fused rings, bridged bicyclic heterocycles, Spiro-compounds containing, for example, the above heterocycles. - As used herein, the term “fused rings” is intended to mean, one ring is a 4-7-membered monocyclic ring which is saturated, partially unsaturated, or unsaturated (aromatic) and comprises a 4-membered heterocycle, 5-membered heterocycle, 6-membered heterocycle, 7- membered heterocycle, or a carbocycle, each fused to a second ring. The second ring is a 5 to 7 membered monocyclic ring which is saturated, partially unsaturated, or unsaturated (aromatic), and comprises a 4-membered heterocycle, 5-membered heterocycle, 6-membered heterocycle, 7-membered heterocycle or a carbocycle. - the “one or more suitable substituents” or “one or more substituents” used either one or more suitable substituents substituted on single carbon or it may be substituted on more than one carbon; - the term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. Substitution selected from hydrogen, deuterium, hydroxy, cyano, halo, nitro, haloalkyl, oxo, (C1-C6)alkyl, (C3-C6)cycloalkyl, aminoalkyl, alkoxyalkyl, alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, alkylsulfonyloxy; - the term “stereoisomers” used anywhere in the specification indicates that compounds of the present invention show (R) and (S) configuration; - the term "polymorph" refers to the ability of the compound of the invention to exist in more than one form or crystal structure. - Compounds of formula (1) may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of formula (1), either as single species or mixtures thereof. - Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers. - Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixture thereof are encompassed with compounds of formula (1). Accordingly, the present invention relates to compounds of the novel compounds of general formula (1), Wherein R1 is independently - R2and R3are independently selected from hydrogen, C1-C6alkyl, C3-C7cycloalkyl, C4-C7heterocycloalkyl, C5-C6heteroaryl, aryl, bicyclic, spirocyclic ring system; alternatively, R2and R3 may combine together to form 3-8 membered cycloalkyl ring, 3-8 membered heterocyclic ring, aryl, bicyclic or spirocyclic ring system; wherein, C1-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C5-C6heteroaryl, aryl, bicyclic, spirocyclic ring system is substituted or unsubstituted with one or more substituents independently selected from halogen, haloalkyl, C1- C6 alkyl, C3-C6 cycloalkyl, -OR5, -SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O) R5, - OC(O)N(R5)2, -C(O)N(R5)2, -N(R5)C(O) R5, -N(R5)C(O)O R5, -N(R5)C(O)N(R5)2, - N(R5)S(O)2(R5), -S(O)R5, -S(O)2R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5,-NO2, =O and -CN; C is independently selected from aryl, 5-6 membered heterocyclic ring; R4 is independently selected from hydrogen, halogen, -OR5, -SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O)R5, - OC(O)N(R5)2, -C(O)N(R5)2, -N(R5)C(O)R5, -N(R5)C(O)OR5, -N(R5)C(O)N(R5)2, - N(R5)S(O)2(R5), -S(O)R5, -S(O)2R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5, -NO2, =O and -CN; C1-C6alkyl, C4-C6heterocycloalkyl, C3-C6carbocycle, each of which is substituted or unsubstituted with one or more substituents independently selected from halogen, -OR5, - SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O)R5, -OC(O)N(R5)2, -C(O)N(R5)2, - N(R5)C(O)R5, -N(R5)C(O)OR5, -N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), -S(O)R5, -S(O)2R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5, -NO2, =O and -CN; C3-C10 carbocycle substituted or unsubstituted with one or more substituents independently selected from halogen, -OR5, - SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O)R5, -OC(O)N(R5)2, -C(O)N(R5)2, - N(R5)C(O)R5, -N(R5)C(O)OR5, -N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), -S(O) R5, -S(O)2R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5,-NO2, =O and -CN; n is selected from 0,1,2,3,4; m is selected from 0, 1; A is selected from 5 to 6 membered heteroaryl, 9 or 10 membered bicyclic heteroaryl, phenyl; Y is selected from O, -CO, -N, C1-C6alkyl or absent; Z1 selected from; Z2 is independently selected , hydrogen, C1-C6-alkyl or absent; --- of Z1 and Z2 is a bond which may be present or absent; Z1and Z2combine together to form 4-7 membered cycloalkene, 4-7 membered cycloalkyne ring; when --- is present, E2and E3are absent; E1, E2 and E3 are selected from hydrogen, C1-C6 alkyl, -OC1-C6 alkyl, C1-C6 haloalkyl, -NC1-C6 alkyl; E1and E3combine together to form 4-7 membered cycloalkyl, 4-7 membered heterocyclic ring; B is selected from (i), (ii); (i) 5-10 membered heteroaryl ring, 5-10 membered heterocyclic ring, 3-7 membered cycloalkyl ring, each of them are substituted or unsubstituted with C1-C6 alkyl, C3-C7 cycloalkyl, C4-C7heterocyclic, bicyclic, spirocyclic ring, halogen, deuterium, -OR5, -SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O) R5, -OC(O)N(R5)2, -C(O)N(R5)2, -N(R5)C(O)R5, - N(R5)C(O)OR5, -N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), -S(O) R5, -S(O)2 R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5,-NO2, =,O and –CN, -P(O)CR5; wherein, if 5-10 membered heteroaryl ring contain nitrogen in ring then nitrogen may further attached to –O; wherein alkyl, cycloalkyl, heterocyclic, bicyclic, spirocyclic ring substituted or unsubstituted with C1-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocyclic, bicyclic, spirocyclic ring, halogen, deuterium, -OR5, -SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O) R5, -OC(O)N(R5)2, - C(O)N(R5)2, -N(R5)C(O)R5, -N(R5)C(O)OR5, -N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), -S(O) R5, -S(O)2 R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5, -NO2, =,O and –CN, -P(O)CR5; (ii) ; selected from (a), (b), (c) and (d); (a) hydrogen; (b) halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, - OC(O)R10, -OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)OR10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), -S(O)R10, -S(O)2R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10, -NO2, - CN; (c) C1-C6alkyl substituted or unsubstituted with one or more substituents independently selected from: halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, -OC(O)R10, -OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)OR10, -N(R10)C(O)N(R10)2, - N(R10)S(O)2(R10), -S(O)R10, -S(O)2R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10,-NO2, - CN; (d) C3-10 carbocycle and 3- to 10-membered heterocycle any of which is substituted or unsubstituted with one or more substituents independently selected from: halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, - OC(O)R10, - OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)OR10, -N(R10)C(O)N(R10)2, - N(R10)S(O)2(R10), -S(O) R10, -S(O)2R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10, -NO2, - CN; R6and R7may combine together to form a 3-8 membered cycloalkyl ring, 4- to 12-membered heterocycle substituted or unsubstituted with one or more substituents independently selected from: halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, - OC(O)R10, - OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)O R10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), - S(O) R10, -S(O)2R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10,-NO2, - CN; and C1-6alkyl substituted or unsubstituted with one or more substituents independently selected from halogen, -OR10, - SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, - OC(O)R10, -OC(O)N(R10)2, - N(R10)C(O)R10, -N(R10)C(O)O R10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), -S(O) R10, -S(O)2R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10, -NO2, - CN; R5 and R10 are independently selected at each occurrence from (I), (II) and (III); (I) hydrogen; (II) C1-6alkyl substituted or unsubstituted with one or more substituents independently selected from: halogen, -OH, -OC1-C6 alkyl, -OC1-C6haloalkyl -NH2, -NO2, =O, -CN, C3-10 carbocycle and 3- to 10-membered heterocycle, wherein the C3-10 carbocycle and 3- to 10-membered heterocycle are substituted or unsubstituted with one or more substituents selected from: halogen, -OH, C1-C6 haloalkyl, -OC1-C6 alkyl, -OC1-C6haloalkyl -NH2, -NO2, =O, and -CN; and (III) C3-10 carbocycle and 3- to 10-membered heterocycle, each of which is substituted or unsubstituted with one or more substituents independently selected from: halogen, -OH, C1- C6haloalkyl, -OC1-C6alkyl, -OC1-C6haloalkyl -NH2, -NO2, =O, -CN; and C1-6alkyl substituted or unsubstituted with one or more substituents independently selected from halogen, -OH, -OC1- C6alkyl, -OC1-C6haloalkyl -NH2, -NO2, =O, and –CN; R8and R9are each independently selected from (a), (b), (c); (a) hydrogen; (b) C1-C6 alkyl substituted or unsubstituted with one or more substituents independently selected from: halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, -OC(O)R10, -OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)OR10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), -S(O)R10, -S(O)2R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10,-NO2, - CN; and C3-10carbocycle and 3- to 10-membered heterocycle any of which is substituted or unsubstituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, - OC(O)R10, -OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)O R10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), -S(O) R10, -S(O)2R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10,-NO2, - CN; (c) C3-10 carbocycle and 3- to 10-membered heterocycle any of which is substituted or unsubstituted with one or more substituents independently selected from: halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, - OC(O)R10, - OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)O R10, - N(R10)C(O)N(R10)2, - N(R10)S(O)2(R10), -S(O) R10, -S(O)2 R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10, -NO2, - CN; C1-6alkyl substituted or unsubstituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, - OC(O)R10, -OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)O R10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), -S(O) R10, -S(O)2 R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10, -NO2, - CN; or R8 and R9 may combine together to form 3-8 membered cycloalkyl ring, 4-12 membered heterocyclic ring, aryl, bicyclic or spirocyclic ring system, wherein, 3-8 membered cycloalkyl ring, 4-12 membered heterocyclic ring, aryl, bicyclic and spirocyclic ring system is substituted or unsubstituted with one or more substituents independently selected from halogen, C1-C6 alkyl, - OR5, -SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O) R5, -OC(O)N(R5)2, -C(O)N(R5)2, -N(R5)C(O) R5, -N(R5)C(O)O R5, -N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), -S(O) R5, -S(O)2R5, -S(O)2N(R5)2, - S(=O)(=NR5)R5, -NO2, =,O and -CN; or C1-C6 alkyl substituted or unsubstituted with one or more substituents independently selected from -OR5, -SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O) R5, -OC(O)N(R5)2, -C(O)N(R5)2, - N(R5)C(O) R5, -N(R5)C(O)O R5, -N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), -S(O) R5, -S(O)2R5, - S(O)2N(R5)2, -S(=O)(=NR5)R5, -NO2, =,O and -CN; M is selected from CH or absent; R11is selected from –NR10COR10, -NR10CON(R10)2,NR10. Further preferred embodiments are those disclosed below: R1is independently selected from hydrogen, deuterium; R2 and R3 are independently selected from C3-C7 cycloalkyl; R2 and R3 may combined to form 3-8 membered cycloalkyl ring; R4 is independently selected from hydrogen, halogen; n is selected from 0, 1, 2; m is selected from 0, 1; A is selected from 5 to 6 membered heteroaryl; Y is selected from C1-C6alkyl or absent; C is selected from phenyl, pyridine, pyrazine, pyridazine; B is selected from (i) 5-10 membered heteroaryl ring substituted with halogen, -C(O)OR5 and -CN; (ii) ; independently selected from hydrogen, C1-C6 alkyl wherein alkyl is substituted with halogen; R6and R7can come together to form a 3-8 membered cycloalkyl ring; R5 and R10 are independently selected at each occurrence from hydrogen, C1-C6 alkyl; R8 and R9 are independently selected at each occurrence from hydrogen, C1-C6 alkyl wherein alkyl is substituted with halogen; R8and R9may combined to form 4-12 membered heterocyclic ring wherein heterocyclic ring is substituted with C1-C6 alkyl; M is selected from CH or absent; R11is selected from –NR10COR10. Particularly useful compounds may be selected from Sr No Structure Chemical name 1. (S)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H- - a - N-((1S)-2-((2-fluoro-4-(1-(methyl(2,2,2- trifluoroethyl)amino)-1-oxopropan-2- - - - - - e- 4-chloro-2-methyl-3-(4-((2S)-2-(4- methylcyclohexyl)-2-(1-(penta-1,4-dien-3-yl)- l) - (S)-N-(1-cycloheptyl-2-((4-(3,5-dimethyl-1H- pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1- )- - ) - - - 2- e- N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-1-(4-methylcyclohexyl)-2- e- - e- (S)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H- pyrazol-4-yl) pyridin-2-yl) amino)-2-oxoethyl)- e- e- - )- - )- (S)-1-(2-cyclobutylideneethyl)-N-(1- cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4- - )- - - - - e- - - 1-(2-cyclobutylideneethyl)-N-((1S)-2-((6-(3,5- dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)- e- e- - - - e- - (S)-N-(1-(4,4-difluorocyclohexyl)-2-((6-(3,5- dimethyl-1H-pyrazol-4-yl) pyridin-3-yl) - - )- e (S)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H- pyrazol-4-yl)-6-fluoropyridin-2-yl) amino)-2- 1- - - 81. N-((S)-1-cycloheptyl-2-((4-((R)-3-(4- methylpiperazin-1-yl)-3-oxo-2- )- e - In an embodiment, the present invention relates to compounds of the novel compounds of general formula (1-A),

[0002] R2, R3, R4, M, m, ation. Any formula or compound described above in the specification having hydrogen anywhere in the structure can be deuterated. Particularly useful compounds may be selected from 86 N-(1-Cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4- yl)phenyl)amino)-2-oxoethyl-1-d)-1-(prop-2-yn-1-yl)- - - - List of Abbreviation DMF: Dimethyl formamide DCM: Dichloromethane EDC : Dichloroethane TFA: Trifluoro acetic acid THF : Tetrahydrofurane DIPEA: Disopropyl ethyl amine EtOAc: Ethyl acetate h: Hour(s) rt : room temperature min: Minute(s) tRet: Retention time HCl: Hydrochloric acid RT: Room temperature [25-30 ºC] Cs2CO3: Cesium carbonate K2CO3 : Potassium carbonate K3PO4: Potassium phosphate TEA: Triethyl amine Instrument details Mass spectrum was recorded on LC-MS 2010-A Shimadzu. NMR spectrum: Bruker Avanc 400 mHz Suitable groups and substituents on the groups may be selected from those described anywhere in the specification. The compounds of the present invention may be prepared using the methods described below, together with conventional techniques known to those skilled in the art of organic synthesis or variation thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to those described below, where all symbols are as defined earlier. Intermediate preparation: Acid intermediate prepared as per the procedure describe below Ethyl 1H-pyrazole-3-carboxylate In a 100 ml single neck round-bottomed flask, 1H-pyrazole-3-carboxylic acid (20.3 g, 181 mmol) was added in EtOH (60 mL) at 0-5 °C. Thionyl chloride (17.18 mL, 235 mmol) was added at 0-5°C. The reaction mixture was stirred at 70 °C for 4 h. After completion of reaction, the solution was concentrated under reduced pressure. Hexane was added to the solid mass and was filtered to get desired product as off white solid. (Yield: 25 g, 98%). ESI-MS: m / z 141.04. (M+H)+Ethyl 1- In a 100 mL single neck round-bottomed flask, ethyl 1H-pyrazole-3-carboxylate (500mg, 3.57 mmol) was added in acetonitrile (5 mL) at 25°C under nitogen atmosphere. Then Cs2CO3 (1744 mg, 5.35 mmol) and propargyl bromide (0.408 ml, 3.57 mmol) was added at 25 °C under nitogen atmosphere. The reaction mixture was stirred at 70 °C, for 2 h. After completion of reaction, the solution was concentrated under reduced pressure to dryness give mixture of two regioisomers. Both the isomers were purified by combiflash chromatography using ethyl acetate in hexane. The desired isomer obtained as oily product. (Yield: 200 mg, 32 %).1H NMR (CDCl3, 400 MHz) δ ppm: 7.57 (1H, d, J = 2Hz), 6.90 (1H, d, J = 2Hz), 5.41 (2H, = 2.4 Hz ), 4.42 - 4.3(2H, m), 2.40 (1H, t, J = 2.4 Hz), 1.41 (3H, t, J = 7.2 Hz); ESI-MS: 179.07 [M+1]+. 1-(Prop-2-yn-1-yl)-1H-pyrazole-5-carboxylic acid In a 100 ml single neck round-bottomed flask, ethyl 1-(prop-2-yn-1-yl)-1H-pyrazole-5- carboxylate (200 mg, 1.122 mmol) was added in tetrahydrofuran (4 ml) and water (4 mL) at 0-5 °C. Lithium hydroxide (40.3 mg, 1.684 mmol) was added at 0-5 °C. The reaction mixture was stirred at room temperature for 12 h. After completion of reaction, organic volatiles were removed under reduced pressure. Dilute HCl solution was added to crude mass, solid product obtained was filtered and dried under reduced pressure. (Yield: 140 mg, 83 %). ESI-MS: 149.03 [M-1]+. Other acid intermediates were prepared following the same reaction condition but using appropriate halides and alcohols. Sr. Acid intermediate Chemical Name A6 1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxylic acid A12 (E)-1-(4,4,4-trifluorobut-2-en-1-yl)-1H-pyrazole-5- carboxylic acid Sr. Amine intermediates Chemical Name N l) - B7 2-(4-amino-1H-pyrazol-1-yl)-N-methyl-N- (2,2,2-trifluoroethyl)propanamide - - B16 6-(3,5-dimethyl-1H-pyrazol-4-yl)-5- fluoropyridin-3-amine e- Amino acid derivatives Sr. Amino acid intermediates Chemical Name No. C1 (2S)-2-amino-2-(4-methylcyclohexyl)acetic acid d General Scheme 1: Synthesis of compounds of general formula (1) d from DCC, EDAC, HATU, HBTU, T3P and like using base selected from TEA, DIEA, pyridine and like in a solvent selected from DCM, EDC and DMF give protected amine derivative [5]. Deprotection of protecting group (Pg) under suitable condition selected from dioxane.HCl, TFA, Pd / C& H(2)resulted in amine compound [6]. Coupling of amine compound [6] with appropriate acid derivative [7] using condition reported above gave titled compound [1]. Intermediate 2 and 3 prepared as per the procedure reported in WO2023283453, WO2020127685, WO2021055376 and as per general method reported in Vogel text book of practical organic chemistry. Example 1: Preparation of (S)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4- yl)phenyl)amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide. Step I: Tert-butyl (S)-(1-cyclohexyl-2-((4-(3,5-dimethyl-1-((2-(trimethylsilyl) ethoxy)methyl)- 1H-pyrazol-4-yl)phenyl)amino)-2-oxoethyl)carbamate. In a 25 mL three neck round-bottomed flask (S)-2-((tert-butoxycarbonyl)amino)-2- cyclohexylacetic acid (1.21g, 4.72 mmol) was added in DMF (2.0 ml) at 25 °C. Pyridine (18 ml) and EDC (3.2g, 15.5 mmol) was added in reaction mixture at 25 °C. 4-(3,5-dimethyl-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)aniline (1.25 g, 3.93 mmol) was added in reaction mixture. The reaction mixture was stirred at 25 °C for 1 h. After completion of reaction, the mixture was quenched in water (100 mL) and aq. layer was extracted with EtOAc. Organic layers were washed with water and brine solution. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford desired solid product. The crude product was purified by combiflash chromatography using ethyl acetate in hexane as mobile phase. (Yield: 2.0 g, 95 %). ESI-MS: 557.35 [M+1]+. Step II: (S)-2- methyl)-1H- pyrazol-4-yl)phenyl)acetamide hydrochloride. In a 25 mL three neck round-bottomed flask, tert-butyl- (S)- (1-cyclohexyl-2-((4-(3,5-dimethyl- 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)phenyl)amino)-2-oxoethyl-1-d)carbamate (200 mg, 0.359 mmol) was added in MeOH (5 mL) at 5-10 °C. To this, 1,4-dioxane hydrochloride (1.195 mL, 3.59 mmol) was added at 25 °C. The reaction mixture was stirred at 25 °C for 2 h. After completion of reaction, the solution was concentrated under reduced pressure to give desired product. (Yield: 140 mg, 80 %). ESI-MS: 457.3 [M+1]+. Step methyl)-1H- pyrazol-4-yl)phenyl)amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide. In a 25 mL three neck round-bottomed flask, 1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxylic acid (27 mg, 0.178 mmol) was added in DMF (2.0 ml) at 5-10 °C. To this, DIPEA (0.085 mL, 0.487 mmol) and 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate (93 mg, 0.243 mmol) was added in reaction mixture at 5-10 °C. (S)-2- amino-2-cyclohexyl-N-(4-(3,5-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- yl)phenyl)acetamide-2-hydrochloride (80 mg, 0.162 mmol) was added in reaction mixture and stirred at 25 °C for 1 h. After completion of reaction, the reaction mixture was quenched in water (20 mL) and aq. layer was extracted with EtOAc. Organic layers were washed with water and brine solution. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford solid product. (Yield: 96 mg). ESI-MS: 589.35 [M+1]+. Step -2-oxoethyl- 1)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide In a 25 mL single neck round-bottomed flask, (S)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)phenyl)amino)-2-oxoethyl-1)-1-(prop-2-yn-1- yl)-1H-pyrazole-5-carboxamide (90 mg, 0.153 mmol) was added in DCM (10.0 ml) at 25 °C. To this, TFA (1.178 mL, 15.28 mmol) was added at 25 °C. The reaction mixture was stirred at 25 °C for 4 h. After completion of reaction, the reaction mixture was quenched in water (20 mL), basified with ammonia and aq. layer was extracted with EtOAc. Organic layers were washed with water and brine solution. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford desired solid product. The crude product was purified by combiflash chromatography using methanol in dichloromethane as mobile phase. (Yield: 40 mg, 76 %).1H NMR (DMSO-d6, 400 MHz) ^ ppm : 12.3(1H, brs), 10.2 (1H, brs), 8.62(1H, d, J = 4.4 Hz), 7.66(2H, t, J = 6.8 Hz),7.56 (1H, d, J = 2.0 Hz), 7.23-7.21(2H, d,d, J1 = 1.6 Hz, J2 = 1.6 Hz), 7.15(1H, d, J = 2.0 Hz), 5.36 (2H, d, J = 2.0 Hz), 4.43(1H, t, J = 8.8 Hz), 3.41-3.79 (1H, m), 3.28 (1H, t, J = 2.4 Hz), 2.17 (6H, s), 1.89-1.83(2H, m), 1.72 (2H, s), 1.62 (2H,s), 1.26-1.17 (4H, m), 1.14-1.01(2H,m). ESI-MS: 459.25 [M+1]+. Example 2: Preparation of N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide. N-((1S)-2-((4-(3,5-dimethyl-1H- -1-(4-methylcyclohexyl)-2- oxoethyl)-1-(prop-2-yn-1-yl)-1H- prepared according to the process reported for example 1 using intermediate selected from A1, B1 and C1. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) ^ ppm: 10.25 (1H, s), 8.64 (1H, d, J = 8 Hz), 7.67 (2H, d, J = 8.8 Hz), d, J = 2 Hz), 7.22 (2H, d, J = 8.4 Hz), 7.15 (1H, d, J = 2 Hz), 5.50 (2H, d, J =1.6 Hz), 4.40 (1H, s), 3.28 (1H, t, J = 2.4 Hz), 2.33 – 2.17 (6H, m), 1.76 - 1.72 (5H, m), 1.24 - 1.22 (4H, m), 0.84 (5H, t, J = 6.4 Hz); ESI-MS: 473.5 [M+H]+. Example 3: Preparation of (S)-4-chloro-3-(4-(2-cyclohexyl-2-(1-(prop-2-yn-1-yl)-1H-pyrazole- 5-carboxamido)acetamido)phenyl)-2-methylpyridine 1-oxide. (S)-4-chloro-3-(4-(2-cyclohexyl- 5-carboxamido) acetamido)phenyl)-2-methylpyridine 1-oxide prepared according to the process reported for example 1 using intermediate selected from A1, B2 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) ^ ppm: 10.45 (1H, s), 8.67(1H, t, J = 8.4 Hz), 8.32 (1H, d, J = 7.2 Hz), 7.80 - 7.75 (2H, m), 7.66 - 7.60 (2H, m), 7.56 - 7.55 (2H, m), 7.53 (1H, s), 5.31 (2H, s), 4.44 (1H, t, J = 8 Hz), 3.29 (1H, s), 2.13 (3H, s), 1.99 - 1.91 (2H, m), 1.88 - 1.84 (2H, m), 1.73 - 1.63 (2H, m), 1.34 - 1.23 (4H, m), 1.18- 1.11 (1H, m); ESI-MS: 506.41 [M]+ Example 4: Preparation of (S)-N-(1-cycloheptyl-2-oxo-2-((4-(1-((2,2,2- trifluoroethyl)carbamoyl)cyclopropyl)phenyl)amino)ethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5- carboxamide. ((S)-N-(1-cycloheptyl-2-oxo-2-( carbamoyl) cyclopropyl) phenyl) amino)ethyl)-1-(prop-2-yn-1-yl)- prepared according to the process reported for example 1 using intermediate selected from A1, B3 and C3. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) ^ ppm: 10.31 (1H, s), 8.64 (1H, t, J = 6.4 Hz ), 7.64 (2H, d, J = 8.8 Hz) (1H, d, J = 2 Hz), 7.28 - 7.26 (3H, m), 7.13 (1H, d, J = 2 Hz), 5.35 (2H, d, J = 4.4 Hz), 4.48 (1H, t, J = 8.8 Hz), 3.78 - 3.74 (2H, m), 3.29 (1H, s), 2.49 - 2.00 (1H, m), 1.74 - 1.72 (1H, m), 1.66 - 1.63 (3H, m), 1.56 - 1.50 (6H, m), 1.48 - 1.40 (4H, m), 1.37 - 1.34 (1H, m), 1.24 - 1.18 (1H, m); ESI-MS: 542.40 [M-H]+. Example 5: Preparation of N-((1S)-2-((2-fluoro-4-(1-oxo-1-((2,2,2-trifluoroethyl) amino)propan-2-yl)phenyl)amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H- pyrazole-5-carboxamide. N-((1S)-2-((2-fluoro-4-(1-oxo- propan-2-yl)phenyl) amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A1, B4 and C1. Titled compound characterized by spectral analysis.1H NMR (400 MHz, DMSO-d6): ^ ppm = 9.93 (s, 1H), 8.67 (t, J = 6.0 Hz, 1H), 8.57 (t, J = 8.4 Hz, 1H), 7.70 (t, J = 8.4 Hz, 1H), 7.55 (d, J = 2.0 Hz, 1H), 7.17 (d, J = 12.0 Hz, 1H), 7.12 (d, J = 2.0 Hz, 1H), 7.08 (d, J = 8.4 Hz, 1H), 5.35 (t, J = 2.4 Hz, 2H), 4.55 (t, J = 8.4 Hz, 1H), 3.90 – 3.86 (m, 2H), 3.70 (d, J = 7.2 Hz, 1H), 3.88 (t, J = 2.4 Hz, 1H), 1.87 – 1.78 (m, 2H), 1.75 – 1.63 (m, 3H), 1.34 (d, J = 6.8 Hz, 3H), 1.28 – 1.18 (m, 2H), 1.11 – 1.02 (m, 1H), 0.91 – 0.83 (m, 5H); ESI-MS = 550.24 [M+H]+. Example 6: Preparation of N-((1S)-2-((2-fluoro-4-(1-(methyl(2,2,2-trifluoroethyl) amino)-1- oxopropan-2-yl)phenyl)amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H- pyrazole-5-carboxamide. N-((1S)-2-((2-fluoro-4-(1- -1-oxopropan-2-yl) phenyl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A1, B5 and C1. Titled compound characterized by spectral analysis.1H NMR (400 MHz, DMSO- d6) ^ ^ ppm : 9.93 (s, 1H), 8.60 (d, J = 8.0 Hz, 1H), 7.76 – 7.75 (m, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.08 – 7.07 (m, 3H), 6.28 – 6.25 (m, 1H), 4.50 – 4.42 (m, 1H), 4.32 – 4.18 (m, 3H), 2.99 (s, 2H), 1.81 – 1.71 (m, 2H), 1.68 – 1.64 (m, 2H), 1.63 – 1.61 (m, 4H), 1.31 – 1.26 (m, 6H), 1.24 – 1.23 (m, 1H), 0.89 – 0.83 (m, 6H); ESI- MS = 578.28 [M+H]+. Example 7: Preparation of N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-vinyl-1H-pyrazole-5-carboxamide. N-((1S)-2-((4-(3,5-dimethyl-1H- amino)-1-(4-methylcyclohexyl)-2- oxoethyl)-1-vinyl-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A3, B1 and C1. Titled compound characterized by spectral analysis.1H NMR (400 MHz, DMSO-d6) ^ ppm : 12.20 (s, 1H), 10.27 (s, 1H), 8.80 (d, J = 8.0 Hz, 1H), 7.96 (dd, J1= 8.8 Hz, J2= 15.6 Hz, 1H), 7.70 (s, 1H), 7.67 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 8.4 Hz, 2H), 7.17 (d, J = 2.0 Hz, 1H), 5.69 (d, J = 15.6 Hz, 1H), 4.92 (d, J = 8.8 Hz, 1H), 4.38 (t, J = 8.4 Hz, 1H), 2.17 (s, 6H), 1.88 – 1.80 (m, 2H), 1.72 – 1.54 (m, 3H), 1.34 – 1.20 (m, 4H), 1.13 – 1.04 (m, 1H), 0.86 (d, J = 6.4 Hz, 3H); ESI-MS = 461.31 [M+H]+. Example 8: Preparation of (S)-N-(2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-(2-methylallyl)-1H-pyrazole-5-carboxamide. (S)-N-(2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl)amino)-1-(4-methylcyclohexyl)-2- oxoethyl)-1-(2-methylallyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A4, B1 and C1. Titled compound characterized by spectral analysis.1H NMR (400 MHz, DMSO-d6) ^ ppm: 12.24 (s, 1H), 10.22 (s, 1H), 8.56 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.53 (s, 1H), 7.22 (d, J = 8.4 Hz, 2H), 7.07 (s, 1H), 5.06 (s, 2H), 4.73 (s, 1H), 4.39 – 4.35 (m, 2H), 2.17 (s, 6H), 1.86 – 1.67 (m, 4H), 1.58 (br s, 4H), 1.34 – 1.21 (m, 2H), 0.87 – 0.85 (m, 6H); ESI-MS = 489.29 [M+H]+. Example 9: Preparation of 3-(4-((2S)-2-(1-(but-3-yn-2-yl)-1H-pyrazole-5-carboxamido)-2- cyclohexylacetamido)phenyl)-4-chloro-2-methyl-1-(l1-oxidaneyl)pyridin-1-ium. 3-(4-((2S)-2-(1-(but-3-yn-2-yl)- -2-cyclohexylacetamido) phenyl)-4- chloro-2-methyl-1-(l1-oxidaneyl)pyridin-1-ium prepared according to the process reported for example 1 using intermediate selected from A2, B2 and C2. Titled compound characterized by spectral analysis.1H NMR (400 MHz, DMSO-d6) ^ ppm: 10.43 (s, 1H), 8.74 – 8.64 (m, 1H), 8.33 (d, J = 7.2 Hz, 1H), 7.80 – 7.75 (m, 2H), 7.59 (d, J = 1.6 Hz, 1H), 7.55 (d, J = 6.8 Hz, 1H), 7.26 (d, J = 7.6 Hz, 2H), 7.12 (d, J = 2.0 Hz, 1H), 6.35 – 6.32 (m, 1H), 4.42 (t, J = 8.8 Hz, 1H), 3.38 – 3.33 (m, 1H), 2.13 (s, 3H), 1.97 – 1.84 (m, 2H), 1.73 (br s, 2H), 1.63 (t, J = 7.6 Hz, 5H), 1.18 – 1.09 (m, 4H), 1.05 – 1.00 (m, 1H); ESI-MS = 520.21 [M+H]+. Example 10: Preparation of 1-(but-3-yn-2-yl)-N-((1S)-2-((2-fluoro-4-(1-(methyl(2,2,2- trifluoroethyl)amino)-1-oxopropan-2-yl)phenyl)amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H- pyrazole-5-carboxamide. 1-(but-3-yn-2-yl)-N-((1S)-2-((2- amino)-1-oxopropan-2- yl)phenyl)amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A2, B5 and C1. Titled compound characterized by spectral analysis.1H NMR (400 MHz, DMSO-d6) ^ ppm: 9.93 (s, 1H), 8.60 (d, J = 8.0 Hz, 1H), 7.76 – 7.75 (m, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.08 – 7.07 (m, 3H), 6.28 – 6.25 (m, 1H), 4.50 – 4.42 (m, 1H), 4.32 – 4.18 (m, 3H), 2.99 (s, 2H), 1.81 – 1.71 (m, 2H), 1.68 – 1.64 (m, 2H), 1.63 – 1.61 (m, 4H), 1.31 – 1.26 (m, 6H), 1.24 – 1.23 (m, 1H), 0.89 – 0.83 (m, 6H); ESI- MS = 578.28 [M+H]+. Example 11: Preparation of 1-(but-2-yn-1-yl)-N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4- yl)phenyl)amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide. 1-(but-2-yn-1-yl)-N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A5, B1 and C1. Titled compound characterized by spectral analysis.1H NMR (400 MHz, DMSO-d6) ^ ppm: 12.23 (s, 1H), 10.23 (s, 1H), 8.60 (d, J = 8.0 Hz, 1H), (d, J = 8.8 Hz, 2H), 7.53 (d, J = 2.0 Hz, 1H), 7.22 (d, J = 8.8 Hz, 2H), 7.93 (d, J = 2.0 Hz, 1H), 5.29 (t, J = 3.6 Hz, 2H), 4.40 (t, J = 8.4 Hz, 1H), 2.15 (s, 6H), 1.89 – 1.85 (m, 2H), 1.72 – 1.60 (m, 7H), 1.11 – 1.03 (m, 4H), 0.86 (d, J = 6.8 Hz, 3H); ESI-MS = 487.21 [M+H]+. Example 12: Preparation of N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide N-((1S)-2-((4-(3,5-dimethyl-1H- -1-(4-methylcyclohexyl)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B1 and C1. Titled compound characterized by spectral analysis. ESI-MS: 501.34 (M+H)+. Example 13: Preparation of 4-chloro-2-methyl-3-(4-((2S)-2-(4-methylcyclohexyl)-2-(1-(penta- 1,4-dien-3-yl)-1H-pyrazole-5-carboxamido) acetamido) phenyl) pyridine 1-oxide 4-chloro-2-methyl-3-(4-((2S)-2-(4-methylcyclohexyl)-2-(1-(penta-1,4-dien-3-yl)-1H-pyrazole-5- carboxamido) acetamido) phenyl) pyridine 1-oxide prepared according to the process reported for example 1 using intermediate selected from A6, B2 and C1. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 10.42 (1H, s), 8.63 (1H, d, J = 6.4 Hz), 8.32 (1H, d, J = 5.6 Hz), – 7.75 (2H, m), 7.55 – 7.52 (2H, m), 7.26 (2H, d, J = 6.8 Hz), 7.07 (1H, d, J = 1.6 Hz), 6.30 – 6.27 (1H, m), 6.61 – 6.59 (1H, m), 5.87 – 5.84 (1H, m), 5.15 – 5.13 (3H, m), 5.11 – 5.03 (1H, m), 4.41 - 4.39 (1H, m), 2.13 (3H, s), 1.85 – 1.83 (2H, m), 1.70 – 1.68 (2H, m), 1.65 – 1.63 (1H, m), 1.36 – 1.35 (1H, m), 1.25 – 1.21 (1H, m), 0.88 – 0.86 (1H, m), 0.85 (5H, br s); ESI-MS: 548.2 [M]+Example 14: Preparation of 1-(cyclopent-3-en-1-yl)-N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4- yl) phenyl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide 1-(cyclopent-3-en-1-yl)-N-( 4-yl) phenyl) amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A7, B1 and C1. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 12.24 (1H, s), 10.23 (1H, s), 8.56 (1H, d, J = 6.4 Hz), 7.67 (2H, d, J = 6.8 Hz), 7.50 (1H, d, J = 1.2 Hz), 7.22 (2H, d, J = 6.8 Hz), 7.00 (1H, d, J = 1.2 Hz), 5.91 – 5.89 (1H, m), 5.71 (2H, s), 4.37 (1H, t, J = 6.8 Hz), 2.77 – 2.72 (2H, m), 2.69 – 2.67 (2H, m), 2.17 (6H, s), 1.89 – 1.86 (2H, m), 1.70 – 1.69 (2H, m), 1.62 – 1.59 (2H, m), 1.23 – 1.09 (2H, m), 1.89 – 1.85 (5H, m); ESI-MS: 501.2 [M+H]+Example 15: Preparation of (S)-4-chloro-3-(4-(2-cyclohexyl-2-(1-(penta-1,4-dien-3-yl)-1H- pyrazole-5-carboxamido) acetamido) phenyl)-2-methylpyridine 1-oxide. (S)-4-chloro-3-(4-(2-cyclohe yrazole-5-carboxamido) acetamido) phenyl)-2-methylpyridine 1-oxide prepared according to the process reported for example 1 using intermediate selected from A6, B2 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 10.41 (1H, s), 8.60 (1H, d, J = 6.4 Hz), 8.33 (1H, d, J = 5.6 Hz), 7.80 – 7.75 (2H, m), 7.55 (2H, d, J = 6.8 Hz), 7.26 (2H, d, J = 8.8 Hz), 7.07 (1H, d, J = 2.0 Hz), 6.31 – 6.27 (1H, m), 6.02 – 6.01 (1H, m), 5.89 – 5.86 (1H, m), 5.16 – 5.11 (3H, m), 5.06 – 5.03 (1H, m), 4.43 (1H, t, J = 6.8 Hz), 2.13 (3H, s), 1.85 – 1.63 (6H, m), 1.24 – 1.18 (5H, m); ESI-MS: 534.2 [M]+Example 16: Preparation of (S)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide . (S)-N-(1-cyclohexyl-2-((4- amino)-2-oxoethyl)-1-(penta- 1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B1 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 10.20 (1H, s), 8.48 (1H, d, J = 6.8 Hz), 7.58 (2H, d, J = 6.8 Hz), 7.49 (1H, s), 7.08 (2H, d, J = 6.8 Hz), 6.94 (1H, s), 5.39 -5.36 (1H, m), 4.43 – 4.42 (1H, m), 4.20 – 4.19 (2H, m), 2.89 (3H, s), 1.80 - 1.78 (1H, m), 1.64 -1.62 (1H, m), 1.52 – 1.50 (3H, m), 1.41 – 1.40 (3H, m), 1.36 – 1.33 (8H, m), 1.27 - 1.23 (4H, m), 1.19 -1.17 (3H, m); ESI-MS: 562.3 [M+H]+. Example 17: Preparation of (S)-N-(1-cycloheptyl-2-((4-(1-(methyl(2,2,2-trifluoroethyl) carbamoyl) cyclopropyl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5- carboxamide. (S)-N-(1-cycloheptyl-2-( cyclopropyl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B6 and C3. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 10.22 (1H, s), 8.55 (1H, d, J = 6.8 Hz), 7.58 (2H, d, J = 6.8 Hz), (1H, s), 7.07 - 7.05 (2H, m), 7.04 (1H, s), 6.29 - 6.26 (1H, m), 6.01 – 5.99 (1H, m), 5.85 – 5.84 (1H, m), 5.14 – 5.10 (3H, m), 5.03 (1H, d, J = 8.4 Hz), 4.45 – 4.43 (1H, m), 4.20 – 4.19 (2H, m), 2.89 (3H, s), 2.02 – 2.01 (1H, m), 1.63 - 1.62 (1H, m), 1.52 - 1.49 (3H, m), 1.39 - 1.38 (3H, m), 1.32 – 1.30 (3H, m), 1.27 - 1.26 (4H, m), 1.19 - 1.17 (2H, m); ESI-MS: 586.2 [M+H]+. Example 18: Preparation of 1-allyl-N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide. 1-allyl-N-((1S)-2-((4-(3,5- -1-(4-methylcyclohexyl)-2- oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A8, B1 and C1. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 12.27 (1H, br s), 10.23 (1H, s), 8.56 (1H, d, J = 6.4 Hz), 7.67 (1H, d, J = 6.8 Hz), 7.52 (1H, s), 7.23 (2H, d, J = 6.4 Hz), 7.09 (1H, s), 5.96 – 5.91 (1H, m), 5.11 – 5.06 (3H, m), 4.93 (1H, d, J = 13.6 Hz), 4.40 - 4.34 (1H, m), 2.18 (6H, s), 1.87 – 1.84 (2H, m), 1.81 – 1.79 (2H, m), 1.71 – 1.69 (1H, m), 1.30 – 1.24 (3H, m), 1.04 – 1.02 (1H, m), 0.87 – 0.86 (4H, m); ESI-MS: 475.20 [M+H]+Example 19: Preparation of (S)-1-(but-2-yn-1-yl)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H- pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide. (S)-1-(but-2-yn-1-yl)-N- 4-yl) phenyl) amino)-2- oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A5, B1 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO- d6, 400 MHz) δ ppm : 12.23 (1H, s), 10.24 (1H, s), 8.60 (1H, d, J = 8.4 Hz), 7.68 – 7.66 (2H, m), 7.53 (1H, d, J = 2.0 Hz), 7.23 – 7.21 (2H, m), 7.09 (1H, d, J = 2.0 Hz), 5.29 (2H, t, J = 2.4 Hz), 4.43 – 4.41 (1H, m), 2.17 (6H, s), 1.86 – 1.85 (2H, m), 1.72 – 1.71 (5H, m), 1.62 – 1.60 (2H, m), 1.17 – 1.11 (5H, m); ESI-MS: 473.25 [M+H]+. Example 20: Preparation of (S)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1-(cyclopent-3-en-1-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cyclohexyl-2-((4- amino)-2-oxoethyl)-1- (cyclopent-3-en-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A7, B1 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 12.23 (1H, s), 10.22 (1H, s), 8.53 (1H, d, J = 8.4 Hz), 7.68 (2H, d, J = 8.4 Hz), 7.50 (1H, d, J = 1.6 Hz), 7.23 (2H, d, J = 8.8 Hz), 7.00 (1H, d, J = 2.0 Hz), 5.91 – 5.89 (1H, m), 5.72 (2H, s), 4.41 (1H, t, J = 6.8 Hz), 2.78 – 2.70 (4H, m), 2.17 (6H, s), 1.89 – 1.87 (2H, m), 1.72 – 1.70 (2H, m), 1.62 – 1.59 (2H, m), 1.25 – 1.23 (2H, m), 1.19 – 1.09 (3H, m); ESI-MS: 487.20 [M+H]+. Example 21: Preparation of (S)-1-allyl-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide. (S)-1-allyl-N-(1-cyclohexyl- phenyl) amino)-2-oxoethyl)- 1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A8, B1 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 12.23 (1H, s), 10.21 (1H, s), 8.53 (1H, d, J = 8.0 Hz), 7.67 (2H, d, J = 8.8 Hz), 7.52 (1H, d, J = 2.0 Hz), 7.22 (2H, d, J = 8.4 Hz), 7.08 (1H, d, J = 2.0 Hz), 5.97 – 5.90 (1H, m), 5.11 – 5.10 (2H, m), 5.08 – 5.06 (1H, m), 4.95 – 4.90 (1H, m), 4.41 (1H, t, J = 7.2 Hz), 2.17 (6H, s), 1.87 – 1.80 (2H, m), 1.73 – 1.70 (2H, m), 1.67 – 1.57 (2H, m), 1.25 – 1.09 (5H, m); ESI-MS: 461.20 [M+H]+Example 22: Preparation of (S)-N-(1-cycloheptyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cycloheptyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1- (penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B1 and C3. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 12.24 (1H, s), 10.23 (1H, s), 8.57 (1H, d, J = 8.4 Hz), 7.67 (2H, d, J = 8.4 Hz), 7.52 (1H, d, J = 2.0 Hz), 7.22 (2H, d, J = 8.8 Hz), 7.07 (1H, d, J = 2.0 Hz), 6.31 – 6.27 (1H, m), 6.07 – 6.03 (1H, m), 5.87 – 5.86 (1H, m), 5.15 – 5.11 (3H, m), 5.06 – 5.03 (1H, m), 4.49 (1H, t, J = 7.2 Hz), 2.17 (6H, s), 1.87 – 1.80 (1H, m), 1.67 – 1.64 (4H, m), 1.53 – 1.51 (8H, m); ESI-MS: 501.20 [M+H]+. Example 23: Preparation of ethyl (S)-2-(4-(4-(2-cyclohexyl-2-(1-(penta-1,4-dien-3-yl)-1H- pyrazole-5-carboxamido) acetamido) phenyl)-3,5-dimethyl-1H-pyrazol-1-yl) acetate. Ethyl (S)-2-(4- pyrazole-5-carboxamido) acetamido) phenyl)-3,5-dimethyl-1H-pyrazol-1-yl) acetate prepared according to the process reported for example 1 using intermediate selected from A6, B8 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: NA, ESI-MS: 573.3 [M+H]+. Example 24: Preparation of (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl) pyridin- 3-yl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cyclohexyl-2-((6- 3-yl) amino)-2-oxoethyl)-1- (penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B9 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 12.03 (1H, s), 10.41 (1H, s), 8.80 (1H, d, J = 2.0 Hz), 8.60 (1H, d, J = 8.4 Hz), 8.07 - 8.05 (1H, m), 7.52 (1H, s), 7.37 (1H, d, J = 8.8 Hz), 7.07 (1H, d, J = 2.0 Hz), 6.35 - 6.25 (1H, m), 6.05 - 5.95 (1H, m), 5.80 - 5.71 (1H, m), 5.16 - 5.03 (4H, m), 4.43 - 4.39 (1H, m), 2.49 (6H, s), 1.71 - 1.61 (4H, m), 1.26 - 1.23 (5H, m), 1.18 - 1.17 (1H, m); ESI-MS: 488.10 [M+H]+. Example 25: Preparation of (S)-2-(4-(4-(2-cyclohexyl-2-(1-(penta-1,4-dien-3-yl)-1H-pyrazole- 5-carboxamido) acetamido) phenyl)-3,5-dimethyl-1H-pyrazol-1-yl) acetic acid. (S)-2-(4-(4-(2- acetamido) phenyl)-3,5-dimethyl-1H-pyrazol-1-yl) acetic acid prepared according to the process reported for example 1 using intermediate selected from A6, B8 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 10.30 (1H, s), 8.66 (1H, s), 7.68 (2H, d, J = 8.4 Hz), 7.51 (1H, s), 7.19 (2H, d, J = 8.4 Hz), 7.08 (1H, s), 6.31 – 6.26 (1H, m), 6.04 – 5.98 (1H, m), 5.88 – 5.92 (1H, m), 5.15 – 5.11 (2H, m), 5.04 (1H, d, J = 10 Hz), 4.73 (2H, s), 4.41(1H, t , J = 8.0 Hz), 2.14 (6H, s), 1.84 – 1.80 (2H, m), 1.71– 1.61 (4H, m), 1.23 – 1.16 (5H, m); ESI-MS: 545.25 [M+H]+. Example 26: Preparation of (S)-1-(2-cyclobutylideneethyl)-N-(1-cyclohexyl-2-((4-(3,5- dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide. (S)-1-(2-cyclobutylideneethyl)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A9, B1 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 12.23 (1H, s), 10.23 (1H, s), 8.52 (1H, d, J = 8.4 Hz), 7.67 (2H, d, J = 8.8 Hz), 7.47 (1H, d, J = 2.0 Hz), 7.22 (2H, d, J = 8.8 Hz), 7.01 (1H, d, J = 2.0 Hz), 5.01 (1H, s), 4.55 – 4.44 (2H, m), 2.17 (6H, s), 1.93 – 1.84 (5H, m), 1.71 – 1.62 (5H, m), 1.36 – 1.30 (2H, m), 1.26 – 1.23 (5H, m), 1.17 – 1.07 (1H, m); ESI-MS: 501.25 [M+H]+. Example 27: Preparation of 1-(2-cyclobutylideneethyl)-N-((1S)-2-((4-(3,5-dimethyl-1H- pyrazol-4-yl) phenyl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide. 1-(2-cyclobutylideneethyl) 4-yl) phenyl) amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A9, B1 and C1. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 12.23 (1H, s), 10.22 (1H, s), 8.54 (1H, d, J = 8.4 Hz), 7.67 (2H, d, J = 8.8 Hz), 7.46 (1H, d, J = 2.0 Hz), 7.22 (2H, d, J = 8.6 Hz), 6.97 (1H, d, J = 2.0 Hz), 5.21 (1H, br s), 4.93 (2H, t, J = 7.2 Hz), 4.39 (1H, t, J = 7.2 Hz), 2.66 – 2.62 (2H, m), 2.17 (6H, s), 1.85 – 1.81 (4H, m), 1.79 – 1.72 (3H, m), 1.26 – 1.23 (4H, m), 1.07 – 1.03 (1H, m), 0.87 – 0.86 (5H, m); ESI-MS: 515.31 [M+H]+Example 28: Preparation of (S)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1-(3-methylbut-2-en-1-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cyclohexyl-2-((4- yl) amino)-2-oxoethyl)-1-(3- methylbut-2-en-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A10, B1 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 12.24 (1H, s), 10.22 (1H, s), 8.35 (1H, d, J = 8.4 Hz), 7.47 (2H, d, J = 2.0 Hz), 7.47 (1H, d, J = 2.0 Hz), 7.23 (2H, d, J = 8.4 Hz), 6.99 (1H, d, J = 2.0 Hz), 5.27 (1H, t, J = 6.8 Hz), 5.08 – 5.06 (2H, m), 4.42 (1H, t, J = 8.8 Hz), 2.17 (6H, s), 1.88 – 1.85 (2H, m), 1.71 – 1.69 (5H, m), 1.62 (5H, br s), 1.24 – 1.23 (4H, m), 1.11 – 1.03 (1H, m); ESI-MS: 489.30 [M+H]+Example 29: Preparation of N-((S)-1-cycloheptyl-2-((4-((R)-3-(4-methylpiperazin-1-yl)-3-oxo- 2-propionamidopropyl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5- carboxamide. N-((S)-1-cycloheptyl-2-( - - propionamidopropyl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B10 and C3. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 10.26 (1H, br s), 9.90 (1H, br s), 8.70 - 8.40 (1H, m), 8.30-8.10 m), 7.52 (3H, t, J =7.6 Hz), 7.51-7.17 (3H, m), 7.11 - 6.98 (2H, m), 6.50 - 6.20 (1H, m), 6.10 - 5.80(1H, m), 5.16 - 5.12(3H, m), 4.90 - 4.70(1H, m), 4.60 - 4.20 (2H, m), 2.89 - 2.84 (2H, dd, J1 = 6.8 Hz, J2 = 7.6Hz), 2.76 - 2.67 (4H, m), 2.09 - 2.03 (4H, dd, J1 = 7.6 Hz, J2 = 7.2 Hz), 1.71 - 1.68 (5H, m), 1.62 (4H, d, J = 10.8 Hz), 1.45 - 1.30 (6H, m), 0.91(4H, t, J = 7.6 Hz); ESI-MS: 632.40 [M+H]+. Example 30: Preparation of (S)-N-(1-cyclohexyl-2-((4-(1-(2-(dimethylamino) ethyl)-3,5- dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5- carboxamide. (S)-N-(1-cyclohexyl-2-( 1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B11 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 10.26 (1H, br s), 8.56 (1H, d, J = 8.0 Hz), 7.70 (1H, d, J = 8.4 Hz), 7.52 (2H, d, J = 2.0 Hz), 7.22 (1H, d, J = 8.8 Hz), 7.07(1H, d, J = 2.0 Hz), 6.30 - 5.86(3H, m), 5.14 (3H, d, J = 5.6 Hz), 5.13 (1H, d, J = 4.4 Hz), 4.41 - 4.35 (3H, m),3.48 (2H, s), 2.84 (5H, s), 2.25 (2H,s), 2.15 (3H, s), 1.91 - 1.61 (6H, m), 1.25 (5H, d, J = 6.8 Hz), 1.17 (1H, d, J = 7.2 Hz); ESI-MS: 558.30 [M+H]+. Example 31: Preparation of N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-(3-methylbut-2-en-1-yl)-1H-pyrazole-5-carboxamide. N-((1S)-2-((4-(3,5- -1-(4-methylcyclohexyl)-2- oxoethyl)-1-(3-methylbut-2-en-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A10, B1 and C1. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 12.24 (1H, s), 10.22 (1H, s), 8.55 (1H, d, J = 8.4 Hz), 7.68 (2H, d, J = 8.4 Hz), 7.47 (1H, d, J = 2.0 Hz), 7.22 (2H, d, J = 8.8 Hz), 6.99 (1H, d, J = 2.0 Hz), 5.27 – 5.26 (1H, m), 5.08 – 5.06 (2H, m), 4.39 (1H, t, J = 8.8 Hz), 2.17 (6H, s), 1.85 – 1.83 (2H, m), 1.71 – 1.69 (5H, m), 1.62 (3H, s), 1.24 – 1.23 (1H, m), 1.11 – 1.07 (3H, m), 0.87 – 0.85 (5H, s); ESI-MS: 503.7 [M+H]+. Example 32: Preparation of (S)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl) pyrazin- 2-yl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cyclohexyl-2-((5- 2-yl) amino)-2-oxoethyl)-1- (penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B12 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 12.4 (1H, s), 10.90 (1H, s), 9.45 (1H, s), 8.56 (1H, d, J = 8 Hz), 8.45 (1H, s), 7.53 (1H, s), 7.06 (1H, s), 6.47 - 6.31 (1H, m), 6.15 - 6.05 (1H, m), 5.85 - 5.75 (1H, m), 5.14 - 5.10 (3H, m), 5.04 - 5.02 (1H, m), 4.75 - 4.62 (1H, m), 3.7 - 3.68 (1H, m), 3.22 - 3.15 (1H, m), 2.33 – 2.32 (6H, m), 1.90 - 1.72 (4H, m), 133 - 1.15 (4H, m); ESI-MS: 489.26 [M+H]+Example 33: Preparation of (S)-N-(1-cyclohexyl-2-((4-(1-(2-methoxyethyl)-3,5-dimethyl-1H- pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cyclohexyl-2-((4-(1-(2-methoxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)- 2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B14 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 10.23 (1H, br s), 8.55 (1H, d, J = 8.4 Hz), 7.68 (2H, d, J = 8.4 (1H, d, J = 2.0 Hz), 7.19 (2H, d, J = 8.4 Hz), 7.07(1H, d, J = 2.0 Hz), 6.30 - 5.90 (3H, m), 5.15 (3H, d, J = 6.0 Hz), 5.12 (1H, d, J = 6.0 Hz), 4.42 (1H, s), 4.14 (2H, t, J = 5.2 Hz), 3.67 - 3.64(3H,m), 3.16 (3H, d, J = 4.4 Hz), 3.14 (1H, d, J = 4.0 Hz), 2.20 (3H, s), 2.11 (3H,s), 1.90 - 1.60 (6H, m), 1.27 - 1.16 (3H, m); ESI-MS: 546.3 [M+H]+. Example 34: (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide hydrochloride. (S)-N-(1-cyclohexyl-2-((6- 3-yl)amino)-2-oxoethyl)-1- (penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide hydrochloride prepared according to the process reported for example 1 using intermediate selected from A6, B9 and C2. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 11.40 (1H, s), 9.19 (1H, d, J = 2.0 Hz), 8.82 (1H, d, J = 8.0 Hz), 8.53 (1H, d, J1 = 2.0 Hz, J2 = 8.8 Hz ), 7.89 (1H, d, J = 8.8 Hz), 7.53 (1H, d, J = 2.4 Hz), 7.16 (1H, d, J = 2.0 Hz), 6.31 - 6.27 (2H, m), 5.99 - 5.96 (1H, m), 5.86 - 5.82 (1H, m), 5.15 - 5.12 (3H, m), 5.06 - 5.03 (1H, m), 4.43 - 4.40 (1H, m), 3.57 (1H, s), 2.35 (6H, s), 1.95 - 1.80 (2H, m), 1.70 - 1.65 (2H, m), 1.65 - 1.62 (2H, m), 1.23 - 1.22 (4H, m), 1.19 - 1.17 (1H, m); ESI-MS: 488.28 [M+H]+. Example 35: Preparation of N-((1S)-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl) pyrazin-2-yl) amino)- 1-(4-methylcyclohexyl)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide. N-((1S)-2-((5-(3,5-dimethyl ino)-1-(4-methylcyclohexyl)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B12 and C1. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 12.3 (1H, s), 10.90 (1H, s), 9.34 (1H, d, J = 1.6 Hz), 8.58 (1H, d, 8.0 Hz), 8.44 (1H, d, J = 1.2 Hz), 7.52 (1H, d, J = 2.4 Hz), 7.06 (1H, d, J = 2 Hz), 6.30 - 6.26 (1H, m), 6.12 - 6.05 (1H, m), 5.95 - 5.82 (1H, m), 5.25 - 5.15 (1H, m), 5.08 - 4.95 (1H, m), 4.64 -4.53 (1H, m), 2.29 (6H, s), 1.90 – 1.8 (2H, m), 1.70 - 1.58 (4H, m), 1.27 - 1.23 (4H, m), 1.15 - 1.05 (1H, m), 0.89 - 0.87 (3H, m); ESI-MS: 503.25 [M+H]+. Example 36: Preparation of N-((1S)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl) pyridin-3-yl) amino)- 1-(4-methylcyclohexyl)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide. N-((1S)-2-((6-(3,5-dimethyl- -1-(4-methylcyclohexyl)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B9 and C1. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.35 (1H, s), 10.61 (1H, s), 8.52 (1H, d, J = 8.0 Hz), 8.25 (1H, d, J = 1.6 Hz), 8.13 (1H, d, J = 8.4 Hz ), 8.72 - 8.70 (1H, m), 7.52 (1H, d, J = 2.0 Hz), 7.05 (1H, d, J = 2.0 Hz), 6.30 - 6.26 (1H, m), 6.03 - 5.90 (1H, m), 5.91 - 5.86 (1H, m), 5.14 - 5.10 (3H, m), 5.05 - 5.02 (1H, m), 4.54 - 4.50 (1H, m), 2.19 (6H, s), 1.81 - 1.72 (4H, m), 1.70 - 1.67 (1H, m), 1.26 - 1.23 (3H, m), 1.12 - 1.05 (1H, m), 0.86 - 0.85 (4H, m); ESI- MS: 502.29 [M+H]+. Example 37: Preparation of (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl) pyridazin-3-yl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cyclohexyl-2-((6- 3-yl) amino)-2-oxoethyl)- 1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B13 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 11.20 (1H, s), 8.56 (1H, d, J = 8 Hz), 8.30 (1H, d, J = 9.2 Hz), 7.73 (1H, d, J = 9.2 Hz), 7.53 (1H, s), 7.07 (1H, d, J = 8 Hz), 6.95 (1H, s), 6.30 - 6.26 (1H, m), 6.02 - 5.97 (1H, m), 5.14 - 5.10 (3H, m), 5.04 – 5.02 (1H, m), 4.67 - 4.60 (1H, m), 2.33 (6H, s), 1.88 - 1.81 (2H, m), 1.71 - 1.62 (2H, m), 1.27 - 1.07 (5H, m); ESI-MS: 489.26 [M+H]+. Example 38: Preparation of 1-(2-(azetidin-3-ylidene) ethyl)-N-((1S)-2-((4-(3,5-dimethyl-1H- pyrazol-4-yl) phenyl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide hydrochloride. 1-(2-(azetidin-3-ylidene) 4-yl) phenyl) amino)-1- (4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide hydrochloride prepared according to the process reported for example 1 using intermediate selected from A11, B1 and C1. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 10.49 (1H, s), 9.60 (2H, br s), 7.89 - 7.80 (1H, m), 7.78 - 7.71 (3H, m), 7.35 - 7.20 (4H, m), 5.70 (1H, s), 4.80 (2H, d, J = 5.6 Hz), 4.55-4.47 (5H, m), 2.26 (6H, s), 1.80 – 1.66 (5H, m), 1.30 – 1.00 (3H, m), 0.89 – 0.83 (5H, m); ESI-MS: 514.28 [M-H]+. Example 39: Preparation of (S)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl) pyridin- 2-yl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cyclohexyl-2-((5- 2-yl) amino)-2-oxoethyl)-1- (penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B23 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.45 (1H, s), 10.61 (1H, s) , 8.51 (1H, d, J = 8 Hz), 8.13 (1H, d, J = 1.8 Hz), 7.72 (1H, d, J = 2.4 Hz), 7.70 (1H, d, J = 2.4 Hz), 7.51 (1H, d, J = 2 Hz), 7.05 (1H, d, J = 2.4 Hz), 6.45 - 6.34 (1H, m), 6.09 - 6.00 (1H, m), 5.9 - 5.78 (1H, m), 5.25 - 5.00 (4H, m), 4.55 - 4.50 (1H, m), 3.2 - 3.1 (1H, m), 2.33 - 2.23 (6H, m), 1.92 - 1.85 (2H, m), 1.72 - 1.65 (3H, m), 1.25 - 1.18 (1H, m), 1.10 - 0.9 (3H, m); ESI-MS: 488.3 [M+H]+. Example 40: Preparation of (S)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6- fluoropyridin-2-yl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cyclohexyl-2-((5- 2-yl) amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B15 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.40 (1H, s), 10.86 (1H, s), 8.53 (1H, d, J = 8 Hz), 8.06 - 8.04 (1H, m), 7.85 (1H, dd, J1 = 8.4 Hz , J2 = 10 Hz), 7.53 (1H, d, J = 2 Hz), 7.05 (1H, d, J = 2.0 Hz), 6.32 - 6.26 (1H, m), 5.99 - 5.85 (1H, m), 5.8 - 5.7 (1H, m), 5.14 - 5.11 (4H, m), 4.54 – 4.41 (1H, m), 2.33 (6H, s), 1.90 - 1.85 (2H, m), 1.75 - 1.58 (4H, m) , 1.24 - 1.169 (4H, m), 1.147 - 1.05 (1H, m); ESI-MS: 506.26 [M+H]+. Example 41: Preparation of (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-5- fluoropyridin-3-yl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cyclohexyl-2-((6- 3-yl) amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B16 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.48 (1H, s), 10.72 (1H, s), 8.66 - 8.62 (2H, m), 8.12 (1H, dd, J1= 2 Hz, J2= 12.4 Hz), 7.53 (1H, d, J = 2 Hz), 7.07 (1H, d, J = 2 Hz), 6.31 - 6.27 (1H, m), 6.05 - 5.98 (1H, m), 5.85 - 5.71 (1H, m), 5.15 - 5.03 (4H, m), 4.5 – 4.44 (1H, m), 2.15 (6H, s), 1.9 - 1.80 (2H, m), 1.71 - 1.65 (3H, m), 1.45 - 1.15 (6H, m), ESI-MS: 506.26 [M+H]+. Example 42: Preparation of (S)-1-(2-cyclobutylideneethyl)-N-(1-cyclohexyl-2-((6-(3,5- dimethyl-1H-pyrazol-4-yl) pyridin-3-yl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide (S)-1-(2-cyclobutylideneethyl)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl) pyridin-3- yl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A9, B9 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.35 (1H, s), 10.43 (1H, s), 8.80 (1H, d, J = 2.0 Hz), 8.59 (1H, d, J = 8.0 Hz), 8.09 - 8.06 (1H, m), 7.46 (1H, d, J = 2.0 Hz ), 7.37 (1H, d, J = 8.4 Hz), 6.97 (1H, d, J = 2.0 Hz), 5.25 - 5.20 (1H, m), 5.02 - 4.89 (2H, m), 4.42 - 4.40 (1H, m), 2.64 - 2.56 (2H, m), 2.54 - 2.51 (2H, m), 2.31 (6H, s), 1.87 - 1.82 (6H, m), 1.80 - 1.79 (2H, m), 1.25 - 1.18 (5H, m); ESI-MS: 502.29 [M+H]+. Example 43: Preparation of N-((1S)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-5-fluoropyridin-3-yl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide N-((1S)-2-((6-(3,5- yl) amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B16 and C1. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.48 (1H, s), 10.71 (1H, s), 8.647 - 8.62 (2H, m), 8.14 (1H, dd, J1 = 2.0 Hz, J2 = 12.0 Hz), 7.53 (1H, d, J = 2.4 Hz), 7.07 (1H, d, J = 2.0 Hz), 6.31-6.27 (1H, m), 6.00 - 5.98 (1H, m), 5.90 - 5.81 (3H, m), 5.14 - 5.12 (1H, m), 5.05 - 4.95 (1H, m), 4.38 - 4.36 (1H, m), 2.15 (6H, s), 1.85 - 1.75 (2H, m), 1.71 - 1.52 (4H, m), 1.4 - 1.3 (3H, m), 1.21 - 1.15 (1H, m), 0.9 - 0.8 (5H, m), ESI-MS: 520.26 [M+H]+. Example 44: Preparation of (S)-N-(1,1-dicyclopropyl-3-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6- fluoropyridin-2-yl) amino)-3-oxopropan-2-yl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5- carboxamide (S)-N-(1,1-dicyclopropyl-3-( -fluoropyridin-2-yl) amino)-3- oxopropan-2-yl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B15 and C6. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.48 (1H, s), 10.91 (1H, s), 8.50 (1H, d, J = 8.8 Hz), 8.04 (1H, J = 6.8 Hz), 7.87 (1H, dd, J1 = 8.4 Hz, J2 = 11.2 Hz), 7.54 (1H, d, J = 2.0 Hz), 7.06 (1H, d, J = 2 Hz), 6.31-6.27 (1H, m), 6.00 - 5.97 (1H, m), 5.87 - 5.83 (1H, m), 5.15 - 5.10 (2H, m), 5.05 - 5.02 (1H, m), 4.98 - 4.81 (1H, m), 2.22 - 2.15 (6H, m), 1.31 - 1.25 (1H, m), 1.01 - 0.8 (3H, m), 0.6 - 0.51 (2H, m), 0.3 - 0.2 (6H, m); ESI-MS: 518.27 [M+H]+. Example 45: Preparation of (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl) pyridin- 3-yl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide ethanesulfonate (S)-N-(1-cyclohexyl-2-((6- 3-yl) amino)-2-oxoethyl)-1- (penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide ethanesulfonate prepared according to the process reported for example 1 using intermediate selected from A6, B9 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 11.00 (1H, s), 9.10 (1H, s), 8.71 (1H, d, J = 7.6 Hz), 8.37 (1H, d, J = 8.0 Hz), 7.54 (1H, d, J = 2.0 Hz ), 7.08 (1H, d, J = 1.6 Hz), 6.31 (1H, s), 6.31 - 6.27 (1H, m), 5.99 - 5.97 (1H, m), 5.86 - 5.76 (1H, m), 5.15 - 5.04 (2H, m), 4.43 - 4.39 (3H, m), 2.44 - 2.39 (2H, m), 2.32 (6H, s), 1.87 - 1.83 (2H, m), 1.85 - 1.71 (2H, m), 1.62 - 1.60 (2H, m), 1.28 - 1.24 (2H, m), 1.17 - 1.11 (3H, m); 1.11 - 1.05 (2H, m), ESI-MS: 488.27 [M+H]+. Example 46: Preparation of (S)-1-(2-cyclobutylideneethyl)-N-(1-cyclohexyl-2-((6-(3,5- dimethyl-1H-pyrazol-4-yl)-5-fluoropyridin-3-yl) amino)-2-oxoethyl)-1H-pyrazole-5- carboxamide (S)-1-(2- 1H-pyrazol-4-yl)-5- fluoropyridin-3-yl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A9, B16 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.48 (1H, s), 10.74 (1H, s), 8.64 (1H, d, J = 8.4 Hz), 8.15 (1H, = 12.4 Hz, J2 = 2.1 Hz), 7.47 (1H, d, J = 2 Hz), 6.95 (2H, d, J = 2 Hz), 5.26 - 5.19 (1H, m), 5.05 - 4.95 (2H, m), 4.4 - 4.3 (1H, m), 2.7 - 2.6 (2H, m), 2.23 - 2.13 (6H, m), 2.00 - 1.95 (2H, m), 1.82 - 1.55 (6H, m), 1.45 - 1.4 (3H, m), 1.39 - 1.25 (4H, m); ESI-MS: 520.29 [M+H]+. Example 47: Preparation of (S)-1-(2-cyclobutylideneethyl)-N-(1-cyclohexyl-2-((5-(3,5- dimethyl-1H-pyrazol-4-yl)-6-fluoropyridin-2-yl) amino)-2-oxoethyl)-1H-pyrazole-5- carboxamide (S)-1-(2- 1H-pyrazol-4-yl)-6- fluoropyridin-2-yl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A9, B15 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.43 (1H, s), 10.85 (1H, s), 8.51 (1H, d, J = 8 Hz), 8.07 - 8.05 (1H, m), 7.88 - 7.85 (1H, m), 7.47 (1H, d, J = 1.6 Hz), 6.94 (1H, d, J = 2 Hz), 5.50 - 5.19 (1H, m), 5.05 - 4.92 (2H, m), 4.52 - 4.49 (1H, m), 2.51 - 2.50 (2H, m), 2.07 - 1.85 (6H, m), 1.80 - 1.82 (6H, m), 1.78 - 1.76 (3H, m), 1.35 - 1.12 (6H, m); ESI- MS: 520.30 [M+H]+. Example 48: Preparation of (S)-1-(2-cyclobutylideneethyl)-N-(1,1-dicyclopropyl-3-((5-(3,5- dimethyl-1H-pyrazol-4-yl)-6-fluoropyridin-2-yl) amino)-3-oxopropan-2-yl)-1H-pyrazole-5- carboxamide (S)-1-(2- 1H-pyrazol-4-yl)-6- fluoropyridin-2-yl) amino)-3-oxopropan-2-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A9, B15 and C6. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.26 (1H, s), 10.89 (1H, s), 8.50 (1H, d, J = 8.4 Hz), 8.05 (1H, d, J = 6.4 Hz), 7.90 - 7.87 (1H, m), 7.48 (1H, d, J = 2.0 Hz), 6.94 (1H, d, J = 2 Hz), 5.21 - 5.20 (1H, m), 5.15 - 5.05 (1H, m), 4.91 - 4.82 (1H, m), 2.63 - 2.61 (2H, m), 2.17 - 2.08 (6H, m), 1.81 - 1.75 (2H, m), 1.30 - 1.20 (3H, m), 1.05 - 0.85 (4H, m), 0.50 - 0.11 (6H, m); ESI-MS: 532.29 [M+H]+. Example 49: Preparation of (S)-N-(1,1-dicyclopropyl-3-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-5- fluoropyridin-3-yl) amino)-3-oxopropan-2-yl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5- carboxamide (S)-N-(1,1-dicyclopropyl-3-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-5-fluoropyridin-3-yl) amino)-3- oxopropan-2-yl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B16 and C6. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.20 (1H, s), 10.74 (1H, s), 8.62 (1H, d, J = 4.4 Hz), 8.11 (2H, = 1.6 Hz), 8.09 (1H, d, J = 2.4 Hz), 7.53 (1H, d, J = 2.0 Hz), 7.08 (1H, d, J = 2 Hz), 6.32 - 6.27 (1H, m), 6.0 - 5.98 (1H, m), 5.87 - 5.81 (1H, m), 5.17 - 5.15 (2H, m), 5.05 - 5.03 (1H, m), 4.80 - 4.75 (1H, m), 2.23 - 2.20 (6H, m), 1.34 - 1.23(6H, m), 0.87 - 0.79 (2H, m), 0.5 - 0.11 (4H, m); ESI-MS: 517.60 [M+H]+. Example 50: Preparation of N-((1S)-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6-fluoropyridin-2-yl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide N-((1S)-2-((5-(3,5- yl) amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B15 and C1. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.24 (1H, s), 10.86 (1H, s), 8.54 (1H, d, J = 8 Hz), 8.04 (1H, d, J = 1.6 Hz), 7.87 - 7.83 (1H, m), 7.53 (1H, d, J = 2.0 Hz), 7.05 (1H, d, J = 2 Hz), 6.45 - 6.25 (1H, m), 6.05 - 5.95 (1H, m), 5.80 - 5.70 (1H, m), 5.14 - 5.11 (2H, m), 5.05 - 5.02 (1H, m), 4.62 - 4.50 (1H, m), 2.23 - 2.20 (6H, m), 1.85 - 1.80 (2H, m), 1.70 - 1.62 (2H, m), 1.59 - 1.52 (2H, m), 1.41 - 1.35 (3H, m), 1.30 - 1.20 (1H, m), 0.9 - 0.7 (4H, m); ESI - MS: 520.28 [M+H]+. Example 51: Preparation of 1-(2-cyclobutylideneethyl)-N-((1S)-2-((6-(3,5-dimethyl-1H- pyrazol-4-yl)-5-fluoropyridin-3-yl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5- carboxamide 1-(2-cyclobutylideneethyl)- ol-4-yl)-5-fluoropyridin-3-yl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A9, B16 and C1. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.42 (1H, s), 10.73 (1H, s), 8.67 - 8.63 (2H, m), 8.16 - 8.12 (1H, m), 7.47 (1H, d, J = 2 Hz), 6.97 (1H, d, J = 2.0 Hz), 5.20 - 5.15 (1H, m), 5.50 - 4.80 (2H, m), 4.37 (1H, t, J = 8.4 Hz), 2.64 - 2.61 (3H, m), 2.56 - 2.51 (5H, m), 2.23 – 2.17 (6H, m), 1.83-1.76 (7H, m), 1.62 - 1.35 (6H, m); ESI-MS: 534.3 [M+H]+. Example 52: Preparation of 1-(2-cyclobutylideneethyl)-N-((1S)-2-((5-(3,5-dimethyl-1H- pyrazol-4-yl)-6-fluoropyridin-2-yl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5- carboxamide 1-(2-cyclobutylideneethyl) 4-yl)-6-fluoropyridin-2-yl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A9, B15 and C1. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.28 (1H, s), 10.84 (1H, s), 8.52 (1H, d, J = 6.8 Hz), 8.06 (1H, = 6.8 Hz), 7.88 - 7.85 (1H, m), 7.47 (1H, d, J = 1.6 Hz), 6.95 (1H, d, J = 2 Hz), 5.25 - 5.19 (1H, m), 5.1 - 4.85 (2H, m), 4.51 - 4.40 (2H, m), 2.60 - 2.51 (3H, m), 2.23 - 2.20 (6H, m), 1.95 - 1.76 (5H, m), 1.60 - 1.52 (3H, m), 1.40 - 1.32 (4H, m), 1.22 - 1.11(4H, m); ESI-MS: 534.3 [M+H]+. Example 53: Preparation of (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-4- fluoropyridin-3-yl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide (S)-N-(1-cyclohexyl-2-((6- 3-yl) amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B17 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.43 (1H, br s), 10.15 (1H, s), 8.86 (1H, d, J = 10.8 Hz), 8.57 (1H, d, J = 8.0 Hz), 7.52 (1H, s), 7.34 (1H, d, J = 11.6 Hz), 7.06 (1H, s), 6.32 – 6.28 (1H, m), 6.05 – 5.99 (1H, m), 5.87 – 5.84 (1H, m), 5.16 – 5.04 (4H, m), 4.58 (1H, t , J = 8.4 Hz), 2.34 (6H, s), 1.89 – 1.64 (6H, m), 1.24 – 1.06 (5H, m); ESI-MS: 506.27 [M+H]+Example 54: Preparation of (S)-N-(1,1-dicyclopropyl-3-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-3-oxopropan-2-yl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide (S)-N-(1,1-dicyclopropyl-3-( amino)-3-oxopropan-2- yl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B1 and C6. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.20 (1H, s), 10.21 (1H, s), 8.51 (1H, d, J = 9.2 Hz), 7.64 (2H, d, = 8.4 Hz), 7.52 (1H, d, J = 2 Hz), 7.23 (2H, d, J = 8.4 Hz), 7.08 (1H, d, J = 2 Hz), 6.32 - 6.25 (1H, m), 6.15 - 6.05 (1H, m), 5.92 - 5.82 (1H, m), 5.28 - 5.15 (3H, m), 5.10 - 5.05 (1H, m), 4.90 - 4.80 (1H, m), 2.25 - 2.15 (6H, m), 1.40 - 1.20 (1H, m), 0.9 - 0.7 (3H, m), 0.6 - 0.4 (6H, m); ESI-MS: 499.28 [M+H]+. Example 55: Preparation of (S)-1-(2-cyclobutylideneethyl)-N-(1,1-dicyclopropyl-3-((4-(3,5- dimethyl-1H-pyrazol-4-yl) phenyl) amino)-3-oxopropan-2-yl)-1H-pyrazole-5-carboxamide (S)-1-(2- 1H-pyrazol-4-yl) phenyl) amino)-3-oxopropan-2-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A9, B1 and C6. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.23 (1H, s) 10.21 (1H, s), 8.50 (1H, d, J = 9.2 Hz), 7.65 (2H, d, J = 8.4 Hz), 7.48 (1H, d, J = 2 Hz), 7.23 (2H, d, J = 8.4 Hz), 6.97 (1H, d, J = 2 Hz), 5.31 - 5.25 (1H, m), 5.02 - 4.87 (3H, m), 2.72 - 2.65 (2H, m), 2.55 - 2.42 (2H, m), 2.25 - 2.20 (6H, m), 1.82 - 1.79 (2H, m), 0.90 - 0.72 (3H, m), 0.65 - 0.52 (3H, m), 0.42 - 0.22 (2H, m); ESI-MS: 513.31 [M+H]+. Example 56: Preparation of 1-(2-cyclobutylideneethyl)-N-((1S)-2-((6-(3,5-dimethyl-1H- pyrazol-4-yl)pyridin-3-yl)amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5- carboxamide 1-(2-cyclobutylideneethyl) 4-yl)pyridin-3-yl)amino)-1- (4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A9, B9 and C1. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.30 (1H, s), 10.40 (1H, s), 8.8 (1H, s), 8.60 (1H, d, J = 8.4 , (1H, d, J = 2.4 Hz), 7.47 – 7.45 (1H, m), 7.37 (1H, d, J = 8.8 Hz), 6.97 (1H, s), 5.25 - 5.20 (1H, m), 5.05 - 4.90 (2H, m), 4.41 - 4.35 (1H, m), 2.71 - 2.68 (2H, m), 2.50 - 2.49 (2H, m), 2.31 - 2.25 (6H, m), 1.82 - 1.78 (7H, m), 1.42 - 1.12 (5H, m), 0.87 - 0.86 (5H, m); ESI-MS: 516.31 [M+H]+Example 57: Preparation of (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-2- fluoropyridin-3-yl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide (S)-N-(1-cyclohexyl-2-((6- 3-yl) amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B18 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.40 (1H, s), 10.11 (1H, s), 8.55 (1H, d, J = 8.4 Hz), 8.34 – 8.30 (1H, m), 7.52 (1H, s), 7.33 (1H, d, J = 8.0 Hz)), 7.06 (1H, s), 6.31 – 6.27 (1H, m), 6.04 – 5.98 (1H, m), 5.87 – 5.83 (1H, m), 5.16 – 5.12 (2H, m), 5.06 – 5.04 (1H, m), 4.59 (1H, t, J = 8.4 Hz), 4.01 – 4.00 (2H, m), 2.34 - 2.32 (5H, m), 1.99 – 1.91 (2H, m), 1.82 – 1.79 (2H, m), 1.72 – 1.63 (2H, m), 1.21 - 1.19 (4H, m), 1.17 – 1.05 (2H, m); ESI-MS: 506.2 [M+H]+. Example 58: Preparation of (S)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6- fluoropyrazin-2-yl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide (S)-N-(1-cyclohexyl-2-((5- 2-yl) amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B19 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 10.79 (1H, s), 8.55 (1H, d, J = 8.0 Hz), 8.47 (1H, d, J = 4.4 Hz), 7.52 (1H, d, J = 1.6 Hz), 7.05 (1H, d, J = 1.2 Hz), 6.31 – 6.27 (1H, m), 6.05 – 6.01 (1H, m), 5.98 – 5.83 (1H, m), 5.16 – 5.12 (3H, m), 5.05 (1H, d, J = 10 Hz) 4.57 (1H, t , J = 8.4 Hz), 2.41 (3H, s), 2.34 (3H, s), 1.90 – 1.62 (6H, m), 1.21 – 1.08 (5H, m); ESI-MS: 507.3 [M+H]+. Example 59: Preparation of ethyl (S)-4-(4-(2-cyclohexyl-2-(1-(penta-1,4-dien-3-yl)-1H- pyrazole-5-carboxamido) acetamido) phenyl)-3-methyl-1H-pyrazole-5-carboxylate ethyl (S)-4-(4-(2- 5-carboxamido) acetamido) phenyl)-3-methyl-1H-pyrazole-5-carboxylate prepared according to the process reported for example 1 using intermediate selected from A6, B20 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 13.26 (1H, s), 10.24 (1H, s), 8.55 (1H, d, J = 8.0 Hz), 7.63 (2H, d, J = 8.4 Hz)), 7.52 (1H, s), 7.21 – 7.10 (2H, m), 7.07 (1H, s), 6.31 – 6.27 (1H, m), 6.01 – 5.98 (1H, m), 5.87 – 5.86 (1H, m), 5.16 – 5.12 (3H, m), 5.06 – 5.04 (1H, m), 4.43 – 4.42 (1H, m), 4.16 – 4.12 (2H, m), 2.18 - 2.14 (3H, m), 1.84 – 1.71 (2H, m), 1.61 – 1.24 (2H, m), 1.17 – 1.14 (2H, m), 0.96 – 0.86 (6H, m), 0.83 – 0.81 (2H, m); ESI-MS: 545.2 [M+H]+. Example 60: Preparation of (S)-4-(4-(2-cyclohexyl-2-(1-(penta-1,4-dien-3-yl)-1H-pyrazole-5- carboxamido) acetamido) phenyl)-N, N,3-trimethyl-1H-pyrazole-5-carboxamide (S)-4-(4-(2-cyclohexyl-2- acetamido) phenyl)-N, N,3-trimethyl-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B20 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.87 (1H, s), 10.23 (1H, s), 8.55 (1H, d, J = 7.6 Hz), 7.63 (2H, d, J = 8.0 Hz), 7.52 (1H, s), 7.20 (2H, d, J = 8.0 Hz), 7.07 (1H, s), 6.31 – 6.27 (1H, m), 6.04 – 6.00 (1H, m), 5.98 - 5.82 (1H, m), 5.16 – 5.03 (4H, m), 4.41 (1H, t, J = 8.4 Hz), 2.90 (3H, s), 2.77 (3H, s), 2.29 - 2.28 (2H, m), 1.83 – 1.80 (1H, m), 1.71 – 1.60 (2H, m), 1.34 – 1.30 (1H, m), 1.24 - 0.99 (7H, m), 0.86 – 0.84 (1H, m); ESI-MS: 544.3 [M+H]+. Example 61: Preparation of (S)-4-(4-(2-cyclohexyl-2-(1-(penta-1,4-dien-3-yl)-1H-pyrazole-5- carboxamido) acetamido) phenyl)-3-methyl-1H-pyrazole-5-carboxylic acid (S)-4-(4-(2-cyclohexyl-2- acetamido) phenyl)-3-methyl-1H-pyrazole-5-carboxylic acid prepared according to the process reported for example 1 using intermediate selected from A6, B20 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 13.30 (2H, br s), 10.24 (1H, s), 8.55 (1H, d, J = 8.4 Hz), 7.62 (2H, d, J = 8.8 Hz), 7.51 (1H, s), 7.24 – 7.21 (2H, m), 7.07 (1H, s), 6.31 – 6.24 (1H, m), 6.05 – 6.01 (1H, m), 5.98 - 5.83 (1H, m), 5.16 – 5.12 (3H, m), 5.06 - 5.04 (1H, m), 4.42 (1H, t, J = 8.8 Hz), 1.84 – 1.72 (3H, m), 1.62 – 1.55 (6H, m), 1.19 – 1.17 (4H, m), 1. 00 - 0.99 (1H, m); ESI-MS: 517.2 [M+H]+. Example 62: Preparation of (S, E)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1-(4,4,4-trifluorobut-2-en-1-yl)-1H-pyrazole-5-carboxamide (S, E)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1- (4,4,4-trifluorobut-2-en-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A12, B1 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.2(1H, br s), 10.22 (1H, br s), 8.64 (1H, d, J = 8 Hz), 7.67-7.59 dd, J1 = 8.0 Hz, J2 = 1.6 Hz), 7.23 - 7.14 (3H, dd, J1 = 4.4 Hz, J2= 1.2 Hz), 6.67 - 6.63 (2H, m), 5.66 - 5.60 (1H, m), 5.27 (2H, t, J = 16 Hz), 4.42 (1H, t, J = 8.4 Hz), 2.17 (6H, s), 1.83 (2H, d, J = 12 Hz),1.71 - 1.61(4H, m), 1.17 (5H, d, J = 7.2 Hz); ESI-MS: 529.29 [M+H]+Example 63: Preparation of (S)-N-(1-(4,4-difluorocyclohexyl)-2-((4-(3,5-dimethyl-1H-pyrazol- 4-yl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide (S)-N-(1-(4,4- 4-yl) phenyl) amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B1 and C7. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.24 (1H, br s), 10.29 (1H, s), 8.69 (1H, d, J = 8.4 Hz), 7.67 (2H, d, J = 8.4 Hz), 7.53 (1H, s), 7.23 (2H, d, J = 8.0 Hz), 7.06 (1H, s), 6.31 – 6.27 (1H, m), 6.01 – 5.98 (1H, m), 5.86 – 5.82 (1H, m), 5.16 – 5.12 (3H, m), 5.05 (1H, d, J = 10 Hz), 4.51 (1H, t , J = 8.8 Hz), 2.17 (6H, s), 2.05 - 1.95 (3H, m), 1.90 – 1.68 (4H, m), 1.46 – 1.24 (2H, m); ESI-MS: 523.4 [M+H]+Example 64: Preparation of (S)-N-(2-((4-(5-cyano-3-methyl-1H-pyrazol-4-yl) phenyl) amino)-1- cyclohexyl-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide (S)-N-(2-((4-(5-cyano-3-me no)-1-cyclohexyl-2-oxoethyl)-1- (penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B21 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 13.81 (1H, s), 10.35 (1H, s), 8.57 (1H, d, J = 8 Hz), 7.76 (2H, d, J = 8.8 Hz), 7.52 (1H, d, J = 2 Hz), 7.41 (2H, d, J = 8.4 Hz), 7.07 (1H, d, J = 2 Hz), 6.31 - 6.27 (1H, m), 6.00 - 5.98 (1H, m), 5.86 - 5.82 (1H, m), 5.25 - 4.98 (4H, m), 4.43 - 4.41 (1H, m), 2.33 (3H, s), 1.84 - 1.61 (6H, m), 1.24 - 1.07 (5H, m); ESI-MS: 498.24 [M+H]+. Example 65: Preparation of (S)-N-(1-(4,4-difluorocyclohexyl)-2-((6-(3,5-dimethyl-1H-pyrazol- 4-yl) pyridin-3-yl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide (S)-N-(1-(4,4- 4-yl) pyridin-3-yl) amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A6, B9 and C7. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.33 (1H, bs), 10.48 (1H, s), 8.80 - 8.74 (2H, m ), 8.08 - 8.05 (1H, dd, J1= 2.8, J2= 2.4 Hz), 7.53 (1H, d, J = 1.6 Hz), 7.37 (1H, d, J = 8.4 Hz), 7.07 (1H, d, J = 2.0 Hz), 6.31 (1H, d, J = 10.8 Hz), 5.84 (1H, d, J = 12.0 Hz), 5.15 – 5.04 (4H, m), 4.52 (1H, t , J = 8.8 Hz), 2.31 (6H, s), 2.04 - 1.88 (3H, m), 1.80 – 1.65 (4H, m), 1.60 – 1.23 (2H, m); ESI-MS: 524.23 [M+H]+. Example 66: Preparation of (S)-1-allyl-N-(2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3- yl)amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide 1-allyl-N-((S)-2-((6-(3,5- 3-yl) amino)-1-((1r,4S)-4- methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A8, B9 and C1. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.48 (1H, s), 10.40 (1H, s), 8.80 (1H, d, J = 82.4 Hz), 8.70 - 8.65 m), 8.06 (1H, d, J = 2.4 Hz), 7.52 – 7.50 (1H, m), 7.37 (1H, d, J = 8.4 Hz), 7.08 (1H, d, J = 2.0 Hz), 6.0 - 5.95 (1H, m), 5.22 - 5.15 (3H, m), 4.95 - 4.82 (1H, m), 4.52 - 4.41 (1H, m), 3.75 - 3.62 (2H, m), 3.2 - 3.1 (2H, m), 2.52 - 2.4 (6H, m), 1.95 - 1.80 (2H, m), 1.70 - 1.62 (3H, m), 1.2 - 1.1 (1H, m), 0.9 - 0.8 (3H, m); ESI-MS: 476.30 [M+H]+. Example 67: Preparation of (S)-N-(1-(4,4-difluorocyclohexyl)-2-((4-(3,5-dimethyl-1H-pyrazol- 4-yl) phenyl) amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide (S)-N-(1-(4,4- 4-yl) phenyl) amino)-2- oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A1, B1 and C7. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.20 (1H, br s), 10.32 (1H, s), 8.77 (1H, d, J = 8.4 Hz), 7.68 (2H, d, J = 8.8 Hz), 7.57 (1H, s), 7.23 (2H, d, J = 8.4 Hz), 7.14 (1H, s), 5.35 (2H, t, J = 2 Hz), 4.53 (1H, t, J = 8.8 Hz), 3.30 (1H, s), 2.11 (6H, s), 2.10 - 2.00 (3H, m), 1.99 – 1.69 (4H, m), 1.59 – 1.30 (2H, m); ESI-MS: 524.23 [M+H]+. Example 68: Preparation of (S)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4- yl)phenyl)amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cyclohexyl-2-((4-(3,5- amino)-2-oxoethyl)-1-(prop-2- yn-1-yl)-1H-pyrazole-5- to the process reported for example 1 using intermediate selected from A1, B1 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.30 (1H, bs), 10.44 (1H, s), 8.80 (1H, s ), 8.69 (1H, d, J = 8.0 Hz), 8.07 (1H, dd, J = 2.4 Hz), 7.56 (1H, s), 7.37 (1H, d, J = 8.4 Hz), 7.15 (1H, s), 5.35 (2H, s), 4.41 (1H, t , J = 8.4, 8.8 Hz), 3.30 (1H, s), 2.31 (6H, s), 1.88-1.80 (2H, m), 1.71-169 (2H, m), 1.65-1.55 (1H, m), 1.40-1.10 (3H, m), 1.00-0.85 (5H, m); ESI-MS: 474.29 [M+H]+. Example 69: Preparation of (S)-1-allyl-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4- yl)pyridin-3-yl)amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide. (S)-1-allyl-N-(1-cyclohexyl-2-((6- 4-yl)pyridin-3-yl)amino)-2- oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A8, B9 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm:1H NMR (DMSO d6) δ ppm: 12.30 (1H, bs), 10.42 (1H, s), 8.79 (1H, s ), 8.59 (1H, d, J = 8.4 Hz), 8.08 (1H, dd, J = 2.8,2.4 Hz), 7.52 (1H, s), 7.37 (1H, d, J = 8.4 Hz), 7.08 (1H, s), 5.97-5.89 (1H, m), 5.11-5.05 (3H, m), 4.92 (1H, d, J = 1.6 Hz), 4.42 (1H, t , J = 8.8 Hz), 2.31 (6H, s), 1.89-1.82 (2H, m), 1.71 (2H, bs), 1.61 (2H, bs), 1.29-1.17 (4H, m), 1.10-1.00 (1H, m); ESI-MS: 462.25 [M+H]+. Example 70: Preparation of (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin- 3-yl)amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cyclohexyl-2-((6-(3,5-dim )pyridin-3-yl)amino)-2-oxoethyl)-1- (prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A1, B9 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.30 (1H, bs), 10.40 (1H, s), 8.80 (1H, s ), 8.67 (1H, d, J = 8 Hz), 8.09 (1H, dd, J = 2.4 Hz), 7.56 (1H, s), 7.37 (1H, d, J = 8.4 Hz), 7.15 (1H, s), 5.36-5.26 (2H, m), 4.45 (1H, t , J = 8.4 Hz), 3.28 (1H, s), 2.31 (6H, s), 1.92-1.88 (2H, m), 1.72 (2H, bs), 1.62 (2H, bs), 1.26-1.18 (5H, m); ESI-MS: 460.40 [M+H]+. Example 71: Preparation of (S)-1-(but-2-yn-1-yl)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H- pyrazol-4-yl)pyridin-3-yl)amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide. (S)-1-(but-2-yn-1-yl)-N-(1- 1H-pyrazol-4-yl)pyridin-3- yl)amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A5, B9 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.4 (1H, bs), 10.46 (1H, s), 8.81 (1H, s ), 8.66 (1H, d, J = 8.0 Hz), 8.08 (1H, dd, J = 2.4 Hz), 7.53 (1H, s), 7.38 (1H, d, J = 8.8 Hz), 7.10 (1H, s), 5.34-5.24 (2H, m), 4.43 (1H, t , J = 8.8 Hz), 2.30 (6H, s), 1.91-1.84 (2H, m), 1.72 (5H, bs), 1.62 (2H, bs), 1.23-1.18 (5H, m), 1.10-1.00 (1H, m); ESI-MS: 474.25 [M+H]+. Example 72: Preparation of (S)-1-allyl-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)- 6-fluoropyridin-2-yl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide. (S)-1-allyl-N-(1-cyclohexyl-2-((5-( ol-4-yl)-6-fluoropyridin-2-yl) amino)- 2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A8, B15 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.4 (1H, bs), 10.46 (1H, s), 8.7-8.6 (1H, m), 8.16 (1H, d, J = 8.0 Hz), 7.8-7.7 (1H, m), 7.55 (1H, d, J = 2.0 Hz), 6.8-6.7 (1H, m), 6.67 (1H, d, J = 2.0 Hz), 5.21-5.14 (4H, m), 4.75-4.6 (1H, m), 3.6-3.5 (1H, s), 2.26 (6H, s), 1.86-1.83 (1H, m), 1.31-1.25 (4H, m), 1.20-1.11 (5H, m); ESI-MS: 480.20 [M+H]+. Example 73: Preparation of (S)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6- fluoropyridin-2-yl) amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide. (S)-N-(1-cyclohexyl-2-((5-(3,5- -6-fluoropyridin-2-yl) amino)-2- oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A1, B15 and C2. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.4 (1H, bs), 10.46 (1H, s), 8.95-8.90 (1H, m), 8.20-8.11 (1H, m), 7.8-7.7 (1H, m), 7.57 (1H, s), 6.92-6.90(1H, m), 6.70 (1H, d, J = 2.0 Hz), 5.45-5.44 (2H, m), 4.80-4.70 (1H, m), 2.24 (6H, s), 1.86-1.85 (1H, m), 1.79-1.78 (4H, m), 1.60-1.56 (3H, m), 1.46-1.23 (4H, m); ESI-MS: 478.00 [M+H]+. Example 74: Preparation of N-((S)-1-cycloheptyl-2-((4-((R)-3-(4-methylpiperazin-1-yl)-3-oxo- 2-propionamidopropyl)benzyl)amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5- carboxamide. N-((S)-1-cycloheptyl-2-((4-((R)- -oxo-2- propionamidopropyl)benzyl)amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A1, B22 and C3. Titled compound characterized by spectral analysis,1H NMR (DMSO d6): 8.65- 8.60 (1H, m), 8.44(1H, d, J = 8.8 Hz), 8.21(1H, d, J=8.4 Hz), (1H, d, J = 2.0 Hz), 7.15 (4H,s), 7.08(1H,d,J=2.0 Hz), 5.4-5.3(2H, m), 4.90-4.80 (1H, m), 4.40-4.30 (1H, m) 4.26 (2H, d, J=6.0 Hz), 3.33-3.31(4H,m), 2.95-2.86(1H, m), 2.80-2.75(1H, m), 2.06-2.01 (3H, m), 1.62- 1.60(5H, m), 1.51-1.50 (5H, m), 1.47-1.36(5H, m), 1.14-1.07(1H, m), 0.89 (3H, t, J = 7.6 Hz); ESI-MS: 618.37 [M+H]+. Example 75: Preparation of N-((1S)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)- 1-(4-methylcyclohexyl)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide. N-((1S)-2-((6-(3,5-dimethyl- -1-(4-methylcyclohexyl)-2- oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A1, B9 and C1. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.30 (1H, bs), 10.44 (1H, s), 8.80 (1H, s ), 8.69 (1H, d, J = 8.0 Hz), 8.07 (1H, dd, J = 2.4 Hz), 7.56 (1H, s), 7.37 (1H, d, J = 8.4 Hz), 7.15 (1H, s), 5.35 (2H, s), 4.41 (1H, t , J = 8.4, 8.8 Hz), 3.30 (1H, s), 2.31 (6H, s), 1.88- 1.80 (2H, m), 1.71-169 (2H, m), 1.65-1.55 (1H, m), 1.40-1.10 (3H, m), 1.00-0.85 (5H, m); ESI- MS: 474.29 [M+H]+. Example 76: Preparation of 1-(but-2-yn-1-yl)-N-((1S)-2-((6-(3,5-dimethyl-1H-pyrazol-4- yl)pyridin-3-yl)amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide. 1-(but-2-yn-1-yl)-N-((1S)-2-( pyridin-3-yl)amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A1, B9 and C1. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.33 (1H, bs), 10.44 (1H, s), 8.80 (1H, s ), 8.66 (1H, d, J = 8.0 Hz), 8.08 (1H, dd, J = 2.4 Hz), 7.53 (1H, s), 7.37 (1H, d, J = 8.8 Hz), 7.10 (1H, s), 5.29 (2H, s), 4.41 (1H, t , J = 8.0, 8.8 Hz), 2.31 (6H, s), 1.88-1.60 (7H, m), 1.40-1.30 (3H, m), 1.29-1.21 (1H, m), 1.00-0.85 (5H, m); ESI-MS: 488.40 [M+H]+. Example 77: Preparation of (S)-1-allyl-N-(1,1-dicyclopropyl-3-((4-(3,5-dimethyl-1H-pyrazol-4- yl)phenyl)amino)-3-oxopropan-2-yl)-1H-pyrazole-5-carboxamide . (S)-1-allyl-N-(1,1-dicyclopropyl- 4-yl)phenyl)amino)-3- oxopropan-2-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A8, B1 and C6. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.30 (1H, bs), 10.2 (1H, s), 8.58 (1H, d, J = 9.2 Hz), 7.65 (1H, d, J = 8.8 Hz), 7.57 (1H, d, J = 2.0 Hz), 7.24 (1H, d, J = 8.4 Hz), 7.14 (1H, d, J = 2.0 Hz), 3.52- 3.41 (2H, m), 2.18 (6H, s), 1.40-1.21 (1H, m), 0.91-0.70 (3H, m), 0.5-0.2 (6H, m); ESI-MS: 471.27 [M+H]+. Example 78: Preparation of (S)-N-(1,1-dicyclopropyl-3-((4-(3,5-dimethyl-1H-pyrazol-4- yl)phenyl)amino)-3-oxopropan-2-yl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide . (S)-N-(1,1-dicyclopropyl-3-((4- yl)phenyl)amino)-3-oxopropan-2- yl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A1, B1 and C6. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.30 (1H, bs), 10.2 (1H, s), 8.58 (1H, d, J = 9.2 Hz), 7.65 (1H, d, J = 8.8 Hz), 7.57 (1H, d, J = 2.0 Hz), 7.24 (1H, d, J = 8.4 Hz), 7.14 (1H, d, J = 2.0 Hz), 3.52- 3.41 (2H, m), 2.18 (6H, s), 1.40-1.21 (1H, m), 0.91-0.70 (3H, m), 0.5-0.2 (6H, m); ESI-MS: 471.27 [M+H]+. Example 79: Preparation of (S)-1-allyl-N-(1-cycloheptyl-2-((4-(3,5-dimethyl-1H-pyrazol-4- yl)phenyl)amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide. . ((S)-1-allyl-N-(1-cycloheptyl-2-( 4-yl)phenyl)amino)-2-oxoethyl)- 1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A8, B1 and C3. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.20 (1H, bs), 10.25 (1H, s), 8.55 (1H, d, J = 8.8 Hz ), 7.66 (2H, d, J = 8.8 Hz), 7.52 (1H, s), 7.22 (2H, d, J = 8.4 Hz), 7.07 (1H, s), 5.95-5.90 (1H, m), 5.11-5.05 (3H, m), 4.94-4.90 (1H, m), 4.48 (1H, t , J = 8.8 Hz), 2.17 (6H, s), 1.80-1.25 (13H, m); ESI-MS: 475.25 [M+H]+. Example 80: Preparation of (S)-N-(1-cycloheptyl-2-((4-(3,5-dimethyl-1H-pyrazol-4- yl)phenyl)amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide. . (S)-N-(1-cycloheptyl-2-((4-(3,5- phenyl)amino)-2-oxoethyl)-1-(prop- 2-yn-1-yl)-1H-pyrazole-5- to the process reported for example 1 using intermediate selected from A1, B1 and C3. Titled compound characterized by spectral analysis,1H NMR (DMSO d6) δ ppm: 12.20 (1H, bs), 10.26 (1H, s), 8.65 (1H, d, J = 8.8 Hz ), 7.67 (2H, d, J = 8.4 Hz), 7.55 (1H, s), 7.22 (2H, d, J = 8.4 Hz), 7.14 (1H, s), 5.36 (2H, d, J = 1.6 Hz), 4.50 (1H, t , J = 8.8 Hz), 3.28 (1H, s), 2.12 (6H, s), 1.85-1.20 (13H, m); ESI-MS: 473.26 [M+H]+. Example 81: Preparation of N-((S)-1-cycloheptyl-2-((4-((R)-3-(4-methylpiperazin-1-yl)-3-oxo- 2-propionamidopropyl)phenyl)amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5- carboxamide. N-((S)-1-cycloheptyl-2-((4-((R)-3- -3-oxo-2- propionamidopropyl)phenyl)amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 1 using intermediate selected from A1, B10 and C3. Titled compound characterized by spectral analysis,1H NMR (DMSO d6): 10.16 (1H, brs), 8.59 (1H, d, J = 8.4Hz), 8.19(1H, d, J = 8.4 Hz), 7.54 t, J=2.0 Hz), 7.12(3H, t, J = 7.2 Hz), 5.39-5.29(2H, m), 4.90-4.84 (1H, d,d, J1 = 8.0 Hz, J2 = 7.2Hz), 4.47 (1H, t, J = 8.4 Hz), 2.88-2.83 (2H, m), 2.74- 2.69(1H, m), 2.20-2.14(2H, m), 2.12-2.02(6H, m), 1.79-1.70 (2H, m), 1.64-1.61(3H, m), 1.55-1.47 (3H, m), 1.28-1.24 (6H, m), 1.06-0.97 (2H, m), 0.97-0.89 (4H, m), 0.84- 0.78(1H,m); ESI-MS: 604.38 [M+H]+. Example 82: Preparation of N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4- yl)phenyl)amino)-2-oxoethyl-1-d)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide. Step I : 2-Amino-2-cyclohexylacetic-2-d acid In a 10 mL single neck round-bottomed flask, 2-amino-2-cyclohexylacetic acid (100 mg, 0.636 mmol) was added in acetic-d3 acid-d (4.0 mL) or acetic acid-d (4.0 mL) at 25 °C. 2- hydroxybenzaldehyde (15.54 mg, 0.127 mmol) was added in reaction mixture at 25 °C. The reaction mixture was stirred at 100 °C for 2 h. After completion of reaction, the solution was concentrated under reduced pressure to dryness. The residue was treated with D2O (2.0 mL) and stirred for 15 min, then diluted with water (4.0 mL). The solution was concentrated under reduced pressure to dryness. MeOH (2.0 ml) was added in residue, solid material was filtered to get desired product. (Yield: 80 mg, 75 %).1H NMR (D2O, 400 MHz) ^ ppm: 0.55 – 0.55 (5H, m), 1.12 – 1.09 (2H, m), 1.21 (3H, bs), (3H, m). ESI-M+ S: 159.3 [M+1] . Step II: Tert-butyl (1-cyclohexyl-2-((4-(3,5-dimethyl-1-((2-(trimethylsilyl)ethoxy) methyl)-1H- pyrazol-4-yl)phenyl)amino)-2-oxoethyl-1-d)carbamate. In a 25 mL single neck round-bottomed flask, 2-((tert-butoxycarbonyl)amino)-2- cyclohexylacetic-2-d acid (90 mg, 0.346 mmol) was added in DMF (2.0 ml) at 25 °C. DIPEA (0.110 mL, 0.630 mmol) and HATU (180 mg, 0.472 mmol) was added in reaction mixture at 25 °C. 4-(3,5-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)aniline (100 mg, 0.315 mmol) was added in reaction mixture. The reaction mixture was stirred at 25 °C for 1 h. After completion of reaction, the mixture was quenched in water (20 mL) and aq. layer was extracted with EtOAc. Organic layers were washed with water and brine solution. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford desired solid product. The crude product was purified by combiflash chromatography using ethyl acetate in hexane as mobile phase. (Yield: 110 mg, 62 %). ESI-MS: 558.9 [M+1]+. Step III: 2- methyl)-1H- pyrazol-4-yl)phenyl)acetamide-2-d hydrochloride. In a 25 mL single neck round-bottomed flask, tert-butyl (1-cyclohexyl-2-((4-(3,5-dimethyl-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)phenyl)amino)-2-oxoethyl-1-d)carbamate (200 mg, 0.359 mmol) was added in MeOH (5 mL) at 5-10 °C. To this, 1,4-dioxane hydrochloride (1.195 mL, 3.59 mmol) was added at 25 °C. The reaction mixture was stirred at 25 °C for 2 h. After completion of reaction, the solution was concentrated under reduced pressure to give desired product. (Yield: 140 mg, 80 %). ESI-MS: 458.3 [M+1]+. Step IV: N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol- 4-yl)phenyl)amino)-2-oxoethyl-1-d)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide. In a 25 mL single neck round-bottomed flask, 1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxylic acid (0.43 mg, 0.283 mmol) was added in DMF (2.0 ml) at 5-10 °C. To this, DIPEA (0.148 mL, 0.850 mmol) and 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3- tetramethylisouronium hexafluorophosphate (0.162 mg, 0.425 mmol) was added in reaction mixture at 5-10 °C. 2-amino-2-cyclohexyl-N-(4-(3,5-dimethyl-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)phenyl)acetamide-2-d hydrochloride (0.14 mg, 0.283 mmol) was added in reaction mixture and stirred at 25 °C or 1 h. After completion of reaction, the reaction mixture was quenched in water (20 mL) and aq. layer was extracted with EtOAc. Organic layers were washed with water and brine solution. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford desired solid product. The crude product was purified by combiflash chromatography using ethyl acetate in hexane as mobile phase. (Yield: 111 mg, 65 %). ESI-MS: 590.4 [M+1]+. Step V: 1-d)-1- (prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide In a 25 mL single neck round-bottomed flask, N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)phenyl)amino)-2-oxoethyl-1-d)-1-(prop-2-yn-1- yl)-1H-pyrazole-5-carboxamide (50 mg, 0.085 mmol) was added in DCM (10.0 ml) at 25 °C. To this, TFA (0.131 mL, 1.695 mmol) was added at 25 °C. The reaction mixture was stirred at 25 °C for 4 h. After completion of reaction, the reaction mixture was quenched in water (20 mL), basified with ammonia and aq. layer was extracted with EtOAc. Organic layers were washed with water and brine solution. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford desired solid product. The crude product was purified by combiflash chromatography using methanol in dichloromethane as mobile phase. (Yield: 32 mg, 76 %).1H NMR (DMSO-d6, 400 MHz) ^ ppm : 10.27 (1H, s), 8.73 (1H, s), 7.68 (2H, d, J = 8.4 Hz ), 7.56 (1H, d, J = 2.4 Hz), 7.23 (2H, d, J = 8.4 Hz), 7.15 (1H, d, J = 2.0 Hz), 5.65 (1H, d, J = 6.4 Hz), 3.28 (1H, t, J = 2.4 Hz ), 2.19 (6H, s,), 1.86 - 1.83 (2H, m), 1.75 - 1.71 (2H, m), 1.60 - 1.50 (2H, m), 1.23 - 1.19 (6H, m), 1.04 - 0.98 (1H, m); ESI-MS: 560.25 [M+1]+. Example 83: Preparation of 1-(but-3-yn-2-yl)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol- 4-yl)phenyl)amino)-2-oxoethyl-1-d)-1H-pyrazole-5-carboxamide. 1-(but-3-yn-2-yl)-N-(1- 4-yl)phenyl)amino)-2- oxoethyl-1-d)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 85 using intermediate selected from A2, B1 and C4. Titled compound characterized by spectral analysis.1H NMR (DMSO-d6, 400 MHz) ^ ppm: 12.23 (1H, br s), 10.24 (1H, s), 8.62 (1H, d, J = 10.8 Hz ), 7.67 (2H, dd, J1 = 2.0 Hz, J2 = 18.8 Hz ), 7.58 (1H, d, J = 1.6 Hz), 7.22 (2H, dd, J1= 1.6 Hz, J2= 8.8 Hz), 7.12 - 7.11 (1H, m), 6.36 - 6.32 (1H, m), 2.17 (6H, s), 1.89 - 1.83 (2H, m), 1.75 - 1.72 (2H, m), 1.64 - 1.60 (5H, m), 1.24 (3H, s), 1.20 - 1.10 (1H, m), 1.04 - 1.01 (2H, m); ESI-MS: 574.27 (M+H)+. Example 84: Preparation of N-(1-cyclohexyl-2-((2-fluoro-4-(1-(methyl(2,2,2-trifluoroethyl) amino)-1-oxopropan-2-yl) phenyl) amino)-2-oxoethyl-1-d)-1-(prop-2-yn-1-yl)-1H-pyrazole-5- carboxamide. N-(1-cyclohexyl-2-((2- amino)-1-oxopropan-2-yl) phenyl) amino)-2-oxoethyl-1-d)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 85 using intermediate selected from A1, B5 and C4. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 9.95 (1H, s), 8.56 (1H, s), 7.76 (1H, m), 7.55 (1H, s), 7.15 - 7.11 m), 7.06 - 7.03 (1H, m), 5.35 (2H, s), 4.18 - 4.10 (3H, m), 2.99 (2H, s), 2.69 (1H, s), 1.85 - 1.83 (2H, m), 1.79 - 1.63 (4H, m), 1.33 - 1.27 (4H, m), 1.24 - 1.17 (4H, m); 1.05 - 1.03 (1H, m); ESI-MS: 551.28 [M+H]+. Example 85: Preparation of 1-(but-3-yn-2-yl)-N-(1-cyclohexyl-2-((2-fluoro-4-(1-(methyl(2,2,2- trifluoroethyl) amino)-1-oxopropan-2-yl) phenyl) amino)-2-oxoethyl-1-d)-1H-pyrazole-5- carboxamide. 1-(but-3-yn-2-yl)-N-(1- trifluoroethyl) amino)-1- oxopropan-2-yl) phenyl) amino)-2-oxoethyl-1-d)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 85 using intermediate selected from A2, B5 and C4. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 9.94 (1H, s), 8.56 (1H, d, J = 10.8 Hz), 7.76 - 7.72 (1H, m), 7.60 (1H, s), 7.14 - 7.04 (3H, m), 6.32 (1H, d, J = 7.2 Hz), 4.30 - 4.18 (3H, m), 2.99 (3H, s), 2.51 (2H, s), 1.86 - 1.83 (2H, m), 1.72 - 1.70 (2H, m), 1.64 - 1.61 (5H, m), 1.29 - 1.27 (2H, m), 1.24 - 1.17 (5H, m); ESI-MS: 565.29 [M+H]+. Example 86: Preparation of N-(2-((4-(4-chloro-2-methyl-1-(l1-oxidaneyl)-1l4-pyridin-3- yl)phenyl)amino)-1-cyclohexyl-2-oxoethyl-1-d)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide. N-(2-((4-(4-chloro-2-methyl-1- yl)phenyl)amino)-1-cyclohexyl-2- oxoethyl-1-d)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide prepared according to the process reported for example 85 using intermediate selected from A1, B2 and C4. Titled compound characterized by spectral analysis.1H NMR (DMSO d6) δ ppm: 10.45 (1H, s), 8.68 (1H, s), 8.32 (1H, d, J = 5.6 Hz), 7.80-7.79 m), 7.57-7.54 (1H, m), 7.27-7.25 (2H, m), 7.16 (1H, d, J = 1.6 Hz), 5.37-5.36 (2H, m), 3.34 (3H, s), 2.13 (3H, s), 1.95-1.80 (1H, m), 1.77-1.73 (2H, m), 1.65-1.63 (2H, m), 1.25-1.19 (2H, m), 0.88-0.86 (3H, m), ESI-MS: 507.03 [M+H]+. The pharmaceutically acceptable salts forming a part of this invention may be prepared by treating the compound of formula (1) with suitable acids in suitable solvents by processes known in the art. The invention is further exemplified by the following examples below, which provides some of the several preferred embodiments of the present invention. These examples are provided merely as representative embodiments and should not be construed to limit the scope of the invention in any way. In-vitro study protocol: To evaluate potential inhibitor of IL- 17A, Human IL-17A / IL-17RA HTRF binding kit (Cisbio, cat no : 64BDIL17PEG) was used, which measures interaction between IL-17A and it's receptor, IL-17RA. In presence of an IL-17A inhibitor, this interaction is perturbed. NCEs were routinely screened using this kit according to the manufacturer's protocol. Briefly, 4 uL of Tag1-IL17A and 2uL of increasing concentration of 10X (with a final 1% DMSO concentration) compound (1nM to 10 uM) were pre-incubated for 1 h at room temperature in low volume white 384 well plate. After that, 4 uL of Tag2-IL17RA were added in each well. Finally 10 uL of premix of detection reagent, which contains 1X each of anti-Tag1 EU cryptate (donor) and anti-Tag2 XL665 antibody (acceptor), were added in each well and plate was incubated in dark for 24 hrs at room temperature. Next day, plate was read in Hidex multimode reader with an excitation wave length of 330 nm and dual emissions wave length of 665 and 620 nm. % inhibition of binding interaction of compounds was calculated from the HTRF ratio, with respect to vehicle, which represents 100% binding. For IC50 determination, % inhibition of binding interaction were fed in Graph Pad prism using a four parameter nonlinear regression analysis. Biological Activity The exemplified compounds belonging to formula (1) demonstrated potent IL17A inhibitory potency. Example No. IC(50) nM Example No. IC(50) nM 316344634 209 48 162 When tested in t , no 7, 8, 23, 25, 32, 33, 37, 38, 39, 45, 46, 47, 51, 58, 59, 60 ,61, 64, 65, 66, 69, 75, 88 exhibit IC50values > 500 nM. The novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, their polymorphs, their racemic mixtures and their optically active forms or their mixtures of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients by techniques and processes and concentrations as are well known. The novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, their polymorphs, their racemic mixtures and their optically active forms or their mixtures of the present invention are useful as a medicament for the inflammatory conditions such as psoriasis, asthma, psoriatic arthritis or rheumatoid arthritis and suitable for humans and other warm-blooded animals, and may be administered either by oral, topical or parenteral administration. The quantity of the active component, that is, The novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, their polymorphs, their racemic mixtures and their optically active forms or their mixtures of the present invention and unit dosage form thereof may be varied or adjusted widely depending upon several factors such as the particular application method, the potency of the particular compound and the desired concentration. Use of the novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, their polymorphs, their racemic mixtures and their optically active forms or their mixtures of the present invention for the treatment of inflammatory conditions such as psoriasis, asthma, psoriatic arthritis or rheumatoid arthritis. A method of treatment of inflammatory conditions such as psoriasis, asthma, psoriatic arthritis or rheumatoid arthritis by administering to a subject in need thereof a therapeutically effective amount of the novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, their polymorphs, their racemic mixtures and their optically active forms or their mixtures of the present invention. The invention relates to IL-17 inhibitor for inflammatory conditions, such as psoriasis, asthma, psoriatic arthritis or rheumatoid arthritis.

Claims

We claim:

1. A novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, their polymorphs, their racemic mixtures and their optically active forms or their mixtures, whereinR1is selected from hydrogen, deuterium and -F; R2 and R3 are selected from hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C5-C6heteroaryl, aryl, bicyclic, spirocyclic ring system; alternatively, R2and R3combine together to form 3-8 membered cycloalkyl ring, 3-8 membered heterocyclic ring, aryl, bicyclic or spirocyclic ring system; wherein, C1-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C5-C6 heteroaryl, aryl, bicyclic, spirocyclic ring system is substituted or unsubstituted with one or more substituents independently selected from halogen, haloalkyl, C1-C6alkyl, C3-C6cycloalkyl, -OR5, -SR5, -N(R5)2, - C(O)R5, -C(O)OR5, -OC(O) R5, -OC(O)N(R5)2, -C(O)N(R5)2, -N(R5)C(O) R5, - N(R5)C(O)O R5, -N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), -S(O)R5, -S(O)2R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5,-NO2, =O and -CN; C is selected from aryl, 5-6 membered heterocyclic ring; R4 is selected from hydrogen, halogen, -OR5, -SR5, -N(R5)2, -C(O)R5, -C(O)OR5, - OC(O)R5, -OC(O)N(R5)2, -C(O)N(R5)2, -N(R5)C(O)R5, -N(R5)C(O)OR5, - N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), -S(O)R5, -S(O)2R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5, -NO2, =O and -CN; C1-C6 alkyl, C4-C6 heterocycloalkyl, C3-C6 carbocycle, each of which is substituted or unsubstituted with one or more substituents independently selected from halogen, -OR5, -SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O)R5, -OC(O)N(R5)2, - C(O)N(R5)2, -N(R5)C(O)R5, -N(R5)C(O)OR5, -N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), -S(O)R5, -S(O)2R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5, -NO2, =O and -CN; C3-C10 carbocycle substituted or unsubstituted with one or more substituents independently selected from halogen, -OR5, -SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O)R5, -OC(O)N(R5)2, - C(O)N(R5)2, -N(R5)C(O)R5, -N(R5)C(O)OR5, -N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), -S(O) R5, -S(O)2R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5, -NO2, =O and -CN; n is selected from 0,1,2,3,4; m is selected from 0, 1; A is selected from 5 to 6 membered heteroaryl, 9 or 10 membered bicyclic heteroaryl, phenyl; Y is selected from O, -CO, -N, C1-C6alkyl or absent; Z1selected from ;Z2 is selected , hydrogen, C1-C6-alkyl or absent;--- of Z1and Z2is a bond which is present or absent; Z1 and Z2 combine together to form 4-7 membered cycloalkene, 4-7 membered cycloalkyne ring; when --- is present, E2and E3are absent; E1, E2and E3are selected from hydrogen, C1-C6alkyl, -OC1-C6alkyl, C1-C6haloalkyl, - NC1-C6 alkyl; E1 and E3 combine together to form 4-7 membered cycloalkyl, 4-7 membered heterocyclic ring; B is selected from (i), (ii); (i) 5-10 membered heteroaryl ring, 5-10 membered heterocyclic ring, 3-7 membered cycloalkyl ring, each of them are substituted or unsubstituted with C1-C6alkyl, C3-C7cycloalkyl, C4-C7heterocyclic, bicyclic, spirocyclic ring, halogen, deuterium, -OR5, -SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O) R5, -OC(O)N(R5)2, -C(O)N(R5)2, - N(R5)C(O)R5, -N(R5)C(O)OR5, -N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), -S(O) R5, - S(O)2R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5,-NO2, =,O and –CN, -P(O)CR5; wherein, if 5-10 membered heteroaryl ring contain nitrogen in ring then nitrogen may further attached to –O; wherein alkyl, cycloalkyl, heterocyclic, bicyclic, spirocyclic ring substituted or unsubstituted with C1-C6alkyl, C3-C7cycloalkyl, C4-C7heterocyclic, bicyclic, spirocyclic ring, halogen, deuterium, -OR5, -SR5, -N(R5)2, -C(O)R5, - C(O)OR5, -OC(O) R5, -OC(O)N(R5)2, -C(O)N(R5)2, -N(R5)C(O)R5, -N(R5)C(O)OR5, -N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), -S(O) R5, -S(O)2 R5, -S(O)2N(R5)2, - S(=O)(=NR5)R5,-NO2, =,O and –CN, -P(O)CR5; (ii) ;from (a), (b), (c) and (d); (a) hydrogen; (b) halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, - OC(O)R10, -OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)OR10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), -S(O)R10, -S(O)2R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10, -NO2, - CN; (c) C1-C6alkyl substituted or unsubstituted with one or more substituents independently selected from: halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, - C(O)-O-C1-6-alkyl, -OC(O)R10, -OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)OR10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), -S(O)R10, -S(O)2R10, -S(O)2N(R10)2, - S(=O)(=NR10)R10,-NO2, - CN; (d) C3-10 carbocycle and 3- to 10-membered heterocycle any of which is substituted or unsubstituted with one or more substituents independently selected from: halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, - OC(O)R10, - OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)OR10, -N(R10)C(O)N(R10)2, - N(R10)S(O)2(R10), -S(O) R10, -S(O)2R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10,-NO2, - CN; R6 and R7 combine together to form a 3-8 membered cycloalkyl ring, 4- to 12-membered heterocycle substituted or unsubstituted with one or more substituents independently selected from: halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6- alkyl, - OC(O)R10, -OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)O R10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), -S(O) R10, -S(O)2 R10, -S(O)2N(R10)2, - S(=O)(=NR10)R10,-NO2, - CN; and C1-6alkyl substituted or unsubstituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, -OC(O)R10, -OC(O)N(R10)2, -N(R10)C(O)R10, - N(R10)C(O)O R10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), -S(O) R10, -S(O)2R10, - S(O)2N(R10)2, -S(=O)(=NR10)R10, -NO2, - CN; R5 and R10 are each selected from (I), (II) and (III); (I) hydrogen; (II) C1-6alkyl substituted or unsubstituted with one or more substituents independently selected from: halogen, -OH, -OC1-C6 alkyl, -OC1-C6haloalkyl -NH2, -NO2, =O, -CN, C3- 10 carbocycle and 3- to 10-membered heterocycle, wherein the C3-10 carbocycle and 3- to 10-membered heterocycle are substituted or unsubstituted with one or more substituents selected from: halogen, -OH, C1-C6 haloalkyl, -OC1-C6 alkyl, -OC1-C6haloalkyl -NH2, - NO2, =O, and -CN; and (III) C3-C10carbocycle and 3- to 10-membered heterocycle, each of which is substituted or unsubstituted with one or more substituents independently selected from: halogen, - OH, C1-C6 haloalkyl, -OC1-C6 alkyl, -OC1-C6 haloalkyl -NH2, -NO2, =O, -CN; and C1-6alkyl substituted or unsubstituted with one or more substituents independently selected from halogen, -OH, -OC1-C6alkyl, -OC1-C6haloalkyl -NH2, -NO2, =O, and –CN; R8 and R9 are each selected from (a), (b), (c); (a) hydrogen;(b) C1-C6 alkyl substituted or unsubstituted with one or more substituents independently selected from: halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, -OC(O)R10, -OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)OR10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), -S(O)R10, -S(O)2R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10, -NO2, - CN; and C3-10 carbocycle and 3- to 10-membered heterocycle any of which is substituted or unsubstituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, - OC(O)R10, -OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)O R10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), -S(O) R10, -S(O)2 R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10, -NO2, - CN; (c) C3-C10carbocycle and 3- to 10-membered heterocycle any of which is substituted or unsubstituted with one or more substituents independently selected from: halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, - OC(O)R10, - OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)O R10, - N(R10)C(O)N(R10)2, - N(R10)S(O)2(R10), -S(O) R10, -S(O)2 R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10, -NO2, - CN; C1-6 alkyl substituted or unsubstituted with one or more substituents independently selected from halogen, -OR10, -SR10, -N(R10)2, -C(O)R10, -C(O)NH2, -C(O)-O-C1-6-alkyl, - OC(O)R10, -OC(O)N(R10)2, -N(R10)C(O)R10, -N(R10)C(O)O R10, - N(R10)C(O)N(R10)2, -N(R10)S(O)2(R10), -S(O) R10, -S(O)2 R10, -S(O)2N(R10)2, -S(=O)(=NR10)R10, -NO2, - CN; or R8and R9combine together to form 3-8 membered cycloalkyl ring, 4-12 membered heterocyclic ring, aryl, bicyclic or spirocyclic ring system, wherein, 3-8 membered cycloalkyl ring, 4-12 membered heterocyclic ring, aryl, bicyclic and spirocyclic ring system is substituted or unsubstituted with one or more substituents independently selected from halogen, C1-C6alkyl, -OR5, -SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O) R5, -OC(O)N(R5)2, -C(O)N(R5)2, -N(R5)C(O) R5, -N(R5)C(O)O R5, -N(R5)C(O)N(R5)2, - N(R5)S(O)2(R5), -S(O) R5, -S(O)2R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5,-NO2, =,O and - CN; or C1-C6 alkyl substituted or unsubstituted with one or more substituents independently selected from -OR5, -SR5, -N(R5)2, -C(O)R5, -C(O)OR5, -OC(O) R5, -OC(O)N(R5)2, - C(O)N(R5)2, -N(R5)C(O) R5, -N(R5)C(O)O R5, -N(R5)C(O)N(R5)2, -N(R5)S(O)2(R5), - S(O) R5, -S(O)2R5, -S(O)2N(R5)2, -S(=O)(=NR5)R5,-NO2, =,O and -CN;M is selected from CH or absent; R11 is selected from –NR10COR10, -NR10CON(R10)2, NR10.

2. The novel compounds of general formula (1) as claimed in claim 1, wherein R1 is hydrogen, deuterium; R2 and R3 are C3-C7 cycloalkyl, R2 and R3 combine together to form 3-8 membered cycloalkyl ring; R4is hydrogen or halogen; n is 0, 1 and 2; m is 0 and 1; A is 5 to 6 membered heteroaryl; Y is C1-C6 alkyl or absent, C is phenyl, pyridine, pyrazine and pyridazine; B is (i) 5-10 membered heteroaryl ring substituted with halogen, -C(O)OR5 and -CN; wherein R6and R7are hydrogen, C1-C6alkyl, wherein alkyl isR6 and R7 combine together to form a 3-8 membered cycloalkyl ring; R5and R10hydrogen, C1-C6alkyl; R8 and R9 are hydrogen, C1-C6 alkyl, wherein alkyl is substituted with halogen; R8 and R9 combined together to form 4-12 membered heterocyclic ring, wherein heterocyclic ring is substituted with C1-C6alkyl; M is CH or absent; R11 is–NR10COR10.

3. Compounds of the formula (1) as claimed in claim 1: (S)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-2-oxoethyl)-1- (prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide; N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-1-(4-methylcyclohexyl)-2- oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide;(S)-4-Chloro-3-(4-(2-cyclohexyl-2-(1-(prop-2-yn-1-yl)-1H-pyrazole-5- carboxamido)acetamido)phenyl)-2-methylpyridine 1-oxide; (S)-N-(1-Cycloheptyl-2-oxo-2-((4-(1-((2,2,2- trifluoroethyl)carbamoyl)cyclopropyl)phenyl)amino)ethyl)-1-(prop-2-yn-1-yl)-1H- pyrazole-5-carboxamide; N-((1S)-2-((2-fluoro-4-(1-oxo-1-((2,2,2-trifluoroethyl)amino)propan-2-yl)phenyl)amino)- 1-(4-methylcyclohexyl)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide; N-((1S)-2-((2-fluoro-4-(1-(methyl(2,2,2-trifluoroethyl)amino)-1-oxopropan-2- yl)phenyl)amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole- 5-carboxamide; N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-1-(4-methylcyclohexyl)-2- oxoethyl)-1-vinyl-1H-pyrazole-5-carboxamide; (S)-N-(2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-1-(4-methylcyclohexyl)-2- oxoethyl)-1-(2-methylallyl)-1H-pyrazole-5-carboxamide; 3-(4-((2S)-2-(1-(but-3-yn-2-yl)-1H-pyrazole-5-carboxamido)-2- cyclohexylacetamido)phenyl)-4-chloro-2-methyl-1-(l1-oxidaneyl)pyridin-1-ium; 1-(but-3-yn-2-yl)-N-((1S)-2-((2-fluoro-4-(1-(methyl(2,2,2-trifluoroethyl)amino)-1- oxopropan-2-yl)phenyl)amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5- carboxamide; 1-(but-2-yn-1-yl)-N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide; N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-1-(4-methylcyclohexyl)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; 4-chloro-2-methyl-3-(4-((2S)-2-(4-methylcyclohexyl)-2-(1-(penta-1,4-dien-3-yl)-1H- pyrazole-5-carboxamido) acetamido) phenyl) pyridine 1-oxide; 1-(cyclopent-3-en-1-yl)-N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-1- (4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide; (S)-4-chloro-3-(4-(2-cyclohexyl-2-(1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamido) acetamido) phenyl)-2-methylpyridine 1-oxide; (S)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)- 1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide;(S)-N-(1-cycloheptyl-2-((4-(1-(methyl(2,2,2-trifluoroethyl) carbamoyl) cyclopropyl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; 1-allyl-N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide; (S)-1-(but-2-yn-1-yl)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)- 1-(cyclopent-3-en-1-yl)-1H-pyrazole-5-carboxamide; (S)-1-allyl-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2- oxoethyl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cycloheptyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)- 1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; ethyl (S)-2-(4-(4-(2-cyclohexyl-2-(1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamido) acetamido) phenyl)-3,5-dimethyl-1H-pyrazol-1-yl) acetate; (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl) pyridin-3-yl) amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-2-(4-(4-(2-cyclohexyl-2-(1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamido) acetamido) phenyl)-3,5-dimethyl-1H-pyrazol-1-yl) acetic acid; (S)-1-(2-cyclobutylideneethyl)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide; 1-(2-cyclobutylideneethyl)-N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)- 1-(3-methylbut-2-en-1-yl)-1H-pyrazole-5-carboxamide; N-((S)-1-cycloheptyl-2-((4-((R)-3-(4-methylpiperazin-1-yl)-3-oxo-2- propionamidopropyl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole- 5-carboxamide; (S)-N-(1-cyclohexyl-2-((4-(1-(2-(dimethylamino) ethyl)-3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-1-(4-methylcyclohexyl)-2- oxoethyl)-1-(3-methylbut-2-en-1-yl)-1H-pyrazole-5-carboxamide;(S)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl) pyrazin-2-yl) amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((4-(1-(2-methoxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide hydrochloride; N-((1S)-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl) pyrazin-2-yl) amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; N-((1S)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl) pyridin-3-yl) amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl) pyridazin-3-yl) amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; 1-(2-(azetidin-3-ylidene) ethyl)-N-((1S)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide hydrochloride; (S)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl) pyridin-2-yl) amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6-fluoropyridin-2-yl) amino)- 2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-5-fluoropyridin-3-yl) amino)- 2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-1-(2-cyclobutylideneethyl)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl) pyridin-3-yl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide; N-((1S)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-5-fluoropyridin-3-yl) amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1,1-dicyclopropyl-3-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6-fluoropyridin-2-yl) amino)-3-oxopropan-2-yl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl) pyridin-3-yl) amino)-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide ethanesulfonate; (S)-1-(2-cyclobutylideneethyl)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-5- fluoropyridin-3-yl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide;(S)-1-(2-cyclobutylideneethyl)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6- fluoropyridin-2-yl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide; (S)-1-(2-cyclobutylideneethyl)-N-(1,1-dicyclopropyl-3-((5-(3,5-dimethyl-1H-pyrazol-4- yl)-6-fluoropyridin-2-yl) amino)-3-oxopropan-2-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1,1-dicyclopropyl-3-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-5-fluoropyridin-3-yl) amino)-3-oxopropan-2-yl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; N-((1S)-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6-fluoropyridin-2-yl) amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; 1-(2-cyclobutylideneethyl)-N-((1S)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-5- fluoropyridin-3-yl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5- carboxamide; 1-(2-cyclobutylideneethyl)-N-((1S)-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6- fluoropyridin-2-yl) amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5- carboxamide; (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-4-fluoropyridin-3-yl) amino)- 2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1,1-dicyclopropyl-3-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-3- oxopropan-2-yl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-1-(2-cyclobutylideneethyl)-N-(1,1-dicyclopropyl-3-((4-(3,5-dimethyl-1H-pyrazol-4- yl) phenyl) amino)-3-oxopropan-2-yl)-1H-pyrazole-5-carboxamide; 1-(2-cyclobutylideneethyl)-N-((1S)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3- yl)amino)-1-(4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)-2-fluoropyridin-3-yl) amino)- 2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6-fluoropyrazin-2-yl) amino)- 2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; ethyl (S)-4-(4-(2-cyclohexyl-2-(1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamido) acetamido) phenyl)-3-methyl-1H-pyrazole-5-carboxylate; (S)-4-(4-(2-cyclohexyl-2-(1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamido) acetamido) phenyl)-N, N,3-trimethyl-1H-pyrazole-5-carboxamide;(S)-4-(4-(2-cyclohexyl-2-(1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamido) acetamido) phenyl)-3-methyl-1H-pyrazole-5-carboxylic acid; (S, E)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)-2- oxoethyl)-1-(4,4,4-trifluorobut-2-en-1-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1-(4,4-difluorocyclohexyl)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)- 2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-N-(2-((4-(5-cyano-3-methyl-1H-pyrazol-4-yl) phenyl) amino)-1-cyclohexyl-2- oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1-(4,4-difluorocyclohexyl)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl) pyridin-3-yl) amino)-2-oxoethyl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; (S)-1-allyl-N-(2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide; (S)-N-(1-(4,4-difluorocyclohexyl)-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl) phenyl) amino)- 2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-2-oxoethyl)-1- (prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide; (S)-1-allyl-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-2- oxoethyl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-2- oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide; (S)-1-(but-2-yn-1-yl)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3- yl)amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide; (S)-1-allyl-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6-fluoropyridin-2-yl) amino)-2-oxoethyl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cyclohexyl-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)-6-fluoropyridin-2-yl) amino)- 2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide; N-((S)-1-cycloheptyl-2-((4-((R)-3-(4-methylpiperazin-1-yl)-3-oxo-2- propionamidopropyl)benzyl)amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5- carboxamide; N-((1S)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide;1-(but-2-yn-1-yl)-N-((1S)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-1-(4- methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide; (S)-1-allyl-N-(1,1-dicyclopropyl-3-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-3- oxopropan-2-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1,1-dicyclopropyl-3-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-3- oxopropan-2-yl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide; (S)-1-allyl-N-(1-cycloheptyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-2- oxoethyl)-1H-pyrazole-5-carboxamide; (S)-N-(1-cycloheptyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-2-oxoethyl)-1- (prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide; N-((S)-1-cycloheptyl-2-((4-((R)-3-(4-methylpiperazin-1-yl)-3-oxo-2- propionamidopropyl)phenyl)amino)-2-oxoethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5- carboxamide; (S)-1-allyl-N-(1,1-dicyclopropyl-3-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3- yl)amino)-3-oxopropan-2-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1,1-dicyclopropyl-3-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-3- oxopropan-2-yl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide; (S)-N-(1,1-dicyclopropyl-3-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-3- oxopropan-2-yl)-1-(penta-1,4-dien-3-yl)-1H-pyrazole-5-carboxamide; N-(2-((4-(4-chloro-2-methyl-1-(λ1-oxidaneyl)-1λ4-pyridin-3-yl)benzyl)amino)-1- cycloheptyl-2-oxo-1λ3-ethyl)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide; N-(1-Cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-2-oxoethyl-1-d)-1- (prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide; 1-(but-3-yn-2-yl)-N-(1-cyclohexyl-2-((4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)- 2-oxoethyl-1-d)-1H-pyrazole-5-carboxamide; N-(1-cyclohexyl-2-((2-fluoro-4-(1-(methyl(2,2,2-trifluoroethyl)amino)-1-oxopropan-2- yl)phenyl)amino)-2-oxoethyl-1-d)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide; 1-(but-3-yn-2-yl)-N-(1-cyclohexyl-2-((2-fluoro-4-(1-(methyl(2,2,2-trifluoroethyl)amino)- 1-oxopropan-2-yl)phenyl)amino)-2-oxoethyl-1-d)-1H-pyrazole-5-carboxamide; N-(2-((4-(4-chloro-2-methyl-1-(l1-oxidaneyl)-1l4-pyridin-3-yl)phenyl)amino)-1- cyclohexyl-2-oxoethyl-1-d)-1-(prop-2-yn-1-yl)-1H-pyrazole-5-carboxamide.

4. Use of the novel compounds of general formula (1) as claimed in claim 1 for the treatment of inflammatory conditions such as psoriasis, asthma, psoriatic arthritis or rheumatoid arthritis.

5. Method of treating inflammatory conditions such as psoriasis, asthma, psoriatic arthritis or rheumatoid arthritis comprising administering to a subject in need thereof a therapeutically effective amount of the novel compounds of general formula (1) as claimed in claim 1 or its suitable pharmaceutical composition.

6. Use of the novel compounds of general formula (1) as claimed in claim 1 in the manufacture of medicament for the treatment of inflammatory conditions such as psoriasis, asthma, psoriatic arthritis or rheumatoid arthritis.

Images